

FOR OFFICIAL USE ONLY

Scientific and Technical Information Center

SEARCH REQUEST FORM

Requester's Full Name: MARK BERCH Examiner #: 59193 Date: 5/9/05
Art Unit: 1624 Phone Number: 2-0663 Serial Number: 10634042
Location (Bldg/Room#): 5C01 (Mailbox #): 5C18 Results Format Preferred (circle): PAPER DISK

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following: MEJ

Title of Invention: _____



Inventors (please provide full names): _____

Earliest Priority Date: _____

Search Topic:

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known.




For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.






$j = 1-3$

$K = 1-3$



$Q = \text{R or } (C_{1-2})$



↑
not in ring



$C_m-N' \text{ (not in ring)}$



RECEIVED
MAY 9 2005
STIC

This Page Blank (uspto)

=> fil reg; d stat que 129; fil capl uspatf toxcenter; s 129
 FILE 'REGISTRY' ENTERED AT 16:36:06 ON 12 MAY 2005
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 11 MAY 2005 HIGHEST RN 850303-40-1
 DICTIONARY FILE UPDATES: 11 MAY 2005 HIGHEST RN 850303-40-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005


Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

 *
 * The CA roles and document type information have been removed from *
 * the IDE default display format and the ED field has been added, *
 * effective March 20, 2005. A new display format, IDERL, is now *
 * available and contains the CA role and document type information. *
 *

Crossover limits have been increased. See HELP CROSSOVER for details.










Experimental and calculated property data are now available. For more
 information enter HELP PROP at an arrow prompt in the file or refer
 to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

L9 STR




VAR G1=C/NH2/26/H
 VAR G2=H/C/N/20/22/23
 VAR G3=O/S
 NODE ATTRIBUTES:
 NSPEC IS RC AT 13
 CONNECT IS E1 RC AT 22
 DEFAULT MLEVEL IS ATOM

```
L12      35177 SEA FILE=REGISTRY SSS FUL L9
L20      STR
```



L24 STR

I will not let them see
 the machine, I will not
 let them see the paper *etc*



*2nd subset
search done
on this
structure*

Page 1-A

CH G15~G5
@88 89 90

Page 2-A

VAR G3=O/S
VAR G4=56/59/60/65/70/75/48/83/84/88
VAR G5=NH2/49/52
REP G6=(1-9) C
REP G8=(0-2) CH
REP G9=(1-3) C
REP G10=(2-10) C
REP G11=(0-4) C
REP G12=(0-3) C
REP G13=(1-4) CH
REP G14=(0-1) CH
REP G15=(1-3) CH


NODE ATTRIBUTES:

NSPEC IS RC AT 13
CONNECT IS E1 RC AT 50
CONNECT IS E1 RC AT 51
CONNECT IS E1 RC AT 53
DEFAULT MLEVEL IS ATOM
GGCAT IS SAT AT 67
GGCAT IS SAT AT 72
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 60



STEREO ATTRIBUTES: NONE
L26 STR



VAR G1=O/S
REP G2=(1-9) CH2
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE
L27 STR



G2 @28

VAR G1=O/S
VAR G2=NH2/14/17/19
REP G3=(0-3) C
VAR G5=NH2/14/17
VPA 28-22/27/23 U
NODE ATTRIBUTES:
CONNECT IS E1 RC AT 15
CONNECT IS E1 RC AT 16
CONNECT IS E1 RC AT 18

DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 25

STEREO ATTRIBUTES: NONE
L29 445 SEA FILE=REGISTRY SUB=L22 SSS FUL (L24 NOT (L26 OR L27))

100.0% PROCESSED 456 ITERATIONS 445 ANSWERS
SEARCH TIME: 00.00.01

FILE 'CAPLUS' ENTERED AT 16:36:06 ON 12 MAY 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 16:36:06 ON 12 MAY 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'TOXCENTER' ENTERED AT 16:36:06 ON 12 MAY 2005
COPYRIGHT (C) 2005 ACS

L31 22 L29


=> dup rem l31
PROCESSING COMPLETED FOR L31
L32 17 DUP REM L31 (5 DUPLICATES REMOVED)
ANSWERS '1-12' FROM FILE CAPLUS
ANSWERS '13-17' FROM FILE USPATFULL

=> d ibib ed abs hitstr 1-17; fil .hom

L32 ANSWER 1 OF 17 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 1
ACCESSION NUMBER: 2003:991509 CAPLUS
DOCUMENT NUMBER: 140:42192
TITLE: Preparation of purinone derivatives as
dipeptidylpeptidase IV (DPP-IV) inhibitors
INVENTOR(S): Yoshikawa, Seiji; Emori, Eita; Matsuura, Fumiyoshi;
Richard, Clark; Ikuta, Hironori; Kira, Kazunobu;
Yasuda, Nobuyuki; Nagakura, Tadashi; Yamazaki, Kazuto
PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
SOURCE: PCT Int. Appl., 376 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003104229	A1	20031218	WO 2003-JP7010	20030603
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS,			

LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH,
 PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 EP 1514552 A1 20050316 EP 2003-733276 20030603
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 BR 2003011697 A 20050322 BR 2003-11697 20030603
~~US 2004116328~~ A1 20040617 US 2003-457002 20030606
 PRIORITY APPLN. INFO.: JP 2002-166069 A 20020606
 JP 2002-209373 A 20020718
 JP 2002-307750 A 20021023
 WO 2003-JP7010 W 20030603
 OTHER SOURCE(S): MARPAT 140:42192
 ED Entered STN: 21 Dec 2003
 GI



I

AB The title compds. I [wherein T1 is an optionally substituted, monocyclic or bicyclic, 4- to 12-membered, heterocyclic group containing one or two nitrogen atoms in the ring; X is optionally substituted C1-6 alkyl, etc.; Z1 and Z2 each independently is nitrogen, CR2; and R1 and R2 each independently is hydrogen, optionally substituted C1-6 alkyl, optionally substituted C1-6 alkoxy, etc.] are prepared Compds. of this invention in vitro showed IC50 values of 0.001 μ M to 1.48 μ M against dipeptidylpeptidase IV.

IT 635715-41-2P 635715-43-4P 635715-48-9P
 635715-52-5P 635715-57-0P 635715-58-1P
 635715-60-5P 635715-62-7P 635715-63-8P
 635715-64-9P 635715-66-1P 635715-68-3P
 635715-79-6P 635715-81-0P 635715-83-2P
 635715-85-4P 635715-87-6P 635715-91-2P
 635715-93-4P 635715-95-6P 635715-97-8P
 635715-99-0P 635716-01-7P 635716-05-1P
 635716-09-5P 635716-11-9P 635716-13-1P
 635716-15-3P 635716-17-5P 635716-19-7P
 635716-23-3P 635716-27-7P 635716-29-9P
 635716-31-3P 635716-33-5P 635716-35-7P
 635716-39-1P 635716-45-9P 635716-47-1P
 635716-53-9P 635716-55-1P 635716-57-3P
 635716-59-5P 635716-65-3P 635716-67-5P
 635716-69-7P 635716-71-1P 635716-73-3P
 635716-75-5P 635716-77-7P 635716-79-9P
 635716-81-3P 635716-86-8P 635716-90-4P
 635716-93-7P 635717-00-9P 635717-02-1P
 635717-05-4P 635717-08-7P 635717-10-1P
 635717-13-4P 635717-16-7P 635717-18-9P

635717-20-3P 635717-22-5P 635717-24-7P
 635717-25-8P 635717-26-9P 635717-28-1P
 635717-30-5P 635717-32-7P 635717-35-0P
 635717-36-1P 635717-37-2P 635717-39-4P
 635717-41-8P 635717-43-0P 635717-45-2P
 635717-46-3P 635717-47-4P 635717-48-5P
 635717-49-6P 635717-50-9P 635717-51-0P
 635717-53-2P 635717-55-4P 635717-57-6P
 635717-59-8P 635717-61-2P 635717-63-4P
 635717-84-9P 635717-86-1P 635717-90-7P
 635717-93-0P 635717-96-3P 635717-99-6P
 635718-02-4P 635718-08-0P 635718-10-4P
 635718-21-7P 635718-23-9P 635718-25-1P
 635718-33-1P 635718-35-3P 635718-37-5P
 635718-39-7P 635718-59-1P 635718-71-7P
 635718-73-9P 635718-77-3P 635718-79-5P
 635719-41-4P 635719-45-8P 635719-47-0P
 635719-53-8P 635719-57-2P 635719-73-2P
 635719-77-6P 635719-79-8P 635719-81-2P
 635719-83-4P 635719-85-6P 635719-87-8P
 635719-89-0P 635719-91-4P 635719-93-6P
 635719-95-8P 635719-97-0P 635720-02-4P
 635720-16-0P 635720-18-2P 635720-22-8P
 635720-25-1P 635720-26-2P 635720-27-3P
 635720-28-4P 635720-29-5P 635720-30-8P
 635720-34-2P 635720-36-4P 635720-38-6P
 635720-40-0P 635720-43-3P 635720-45-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(préparation of purinone derivs. as dipeptidylpeptidase IV inhibitors)


RN 635715-41-2 CAPLUS

CN Acetic acid, [[7-(2-chlorophenyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]oxy]-, ethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635715-40-1


CMF C20 H23 Cl N6 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635715-43-4 CAPLUS
 CN Acetic acid, [[7-(2-chlorophenyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]oxy]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635715-42-3


CMF C18 H19 Cl N6 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635715-48-9 CAPLUS
 CN Benzeneacetic acid, α -[[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]oxy]-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635715-47-8


CMF C23 H26 N6 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635715-52-5 CAPLUS

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-2-(1-methylpropoxy)-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635715-51-4


CMF C18 H26 N6 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635715-57-0 CAPLUS

CN Butanoic acid, 2-[[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]oxy]-, ethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635715-56-9


CMF C20 H28 N6 O4



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 635715-58-1 CAPLUS

CN Propanoic acid, 2-[[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 635715-60-5 CAPLUS

CN Propanoic acid, 2-[[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]oxy]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635715-59-2


CMF C17 H22 N6 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635715-62-7 CAPLUS

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-2-methoxy-1-methyl-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635715-61-6


CMF C15 H20 N6 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 635715-63-8 CAPLUS

CN 6H-Purin-6-one, 7-(2-butynyl)-2-ethoxy-1,7-dihydro-1-methyl-8-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 635715-64-9 CAPLUS

CN Acetic acid, [[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 635715-66-1 CAPLUS

CN Acetic acid, [[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]oxy]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635715-65-0


CMF C16 H20 N6 O4



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 635715-68-3 CAPLUS
 CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-2-(2-methoxyethoxy)-1-methyl-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 635715-67-2
 CMF C17 H24 N6 O3



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 635715-79-6 CAPLUS
 CN 1H-Purine-2-acetic acid, 7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-, ethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 635715-78-5
 CMF C18 H24 N6 O3



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 635715-81-0 CAPLUS
 CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1,2-dimethyl-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 635715-80-9
 CMF C15 H20 N6 O



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 635715-83-2 CAPLUS
 CN 6H-Purin-6-one, 2-butyl-7-(2-butynyl)-1,7-dihydro-1-methyl-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 635715-82-1
 CMF C18 H26 N6 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635715-85-4 CAPLUS

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-2-(phenylmethyl)-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635715-84-3


CMF C21 H24 N6 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635715-87-6 CAPLUS

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-2-(2-phenylethyl)-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635715-86-5


CMF C22 H26 N6 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635715-91-2 CAPLUS

CN 6H-Purin-6-one, 2-amino-7-(2-butynyl)-1,7-dihydro-1-methyl-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635715-90-1


CMF C14 H19 N7 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635715-93-4 CAPLUS

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-2-(methylamino)-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635715-92-3


CMF C15 H21 N7 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635715-95-6 CAPLUS

CN 6H-Purin-6-one, 7-(2-butynyl)-2-(dimethylamino)-1,7-dihydro-1-methyl-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635715-94-5


CMF C16 H23 N7 O



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 635715-97-8 CAPLUS
 CN Glycine, N-[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]-, ethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 635715-96-7
 CMF C18 H25 N7 O3



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 635715-99-0 CAPLUS
 CN Glycine, N-[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 635715-98-9
 CMF C16 H21 N7 O3



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 635716-01-7 CAPLUS
CN Glycine, N-[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]-N-methyl-, ethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 635716-00-6
CMF C19 H27 N7 O3



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 635716-05-1 CAPLUS
CN Glycine, N-[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]-N-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 635716-04-0
CMF C17 H23 N7 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635716-09-5 CAPLUS

CN Alanine, N-[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-08-4


CMF C18 H25 N7 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 635716-11-9 CAPLUS


CN Alanine, N-[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-

purin-2-yl]-2-methyl-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-10-8


CMF C19 H27 N7 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 635716-13-1 CAPLUS


CN L-Alanine, N-[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]-, ethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 635716-12-0

CMF C19 H27 N7 O3

Absolute stereochemistry.



CM 2


CRN 76-05-1
CMF C2 H F3 O2

RN 635716-15-3 CAPLUS
CN L-Alanine, N-[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 635716-14-2
CMF C17 H23 N7 O3

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 635716-17-5 CAPLUS
CN β-Alanine, N-[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]-, ethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 635716-16-4
CMF C19 H27 N7 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635716-19-7 CAPLUS

CN 6H-Purin-6-one, 7-(2-butynyl)-2-[(2-ethoxyethyl)amino]-1,7-dihydro-1-methyl-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-18-6


CMF C18 H27 N7 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 635716-23-3 CAPLUS


CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-2-[(phenylmethyl)amino]-

8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-22-2


CMF C21 H25 N7 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635716-27-7 CAPLUS

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-2-[methyl (phenylmethyl)amino]-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-26-6


CMF C22 H27 N7 O



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 635716-29-9 CAPLUS
 CN 6H-Purin-6-one, 7-(2-butynyl)-2-[[[4-chlorophenyl)methyl]amino]-1,7-dihydro-1-methyl-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 635716-28-8
 CMF C21 H24 Cl N7 O



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 635716-31-3 CAPLUS
 CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-2-[[[4-methoxyphenyl)methyl]amino]-1-methyl-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 635716-30-2
 CMF C22 H27 N7 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635716-33-5 CAPLUS

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-2-[(2-phenylethyl)amino]-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-32-4


CMF C22 H27 N7 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635716-35-7 CAPLUS

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-2-[methyl(2-phenylethyl)amino]-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-34-6


CMF C23 H29 N7 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635716-39-1 CAPLUS

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-8-(1-piperazinyl)-2-[(2-pyridinylmethyl)amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-38-0


CMF C20 H24 N8 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635716-45-9 CAPLUS

CN 6H-Purin-6-one, 7-(2-butynyl)-2-(diethylamino)-1,7-dihydro-1-methyl-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-44-8


CMF C18 H27 N7 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635716-47-1 CAPLUS

CN 6H-Purin-6-one, 7-(2-butynyl)-2-(ethylmethyamino)-1,7-dihydro-1-methyl-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-46-0


CMF C17 H25 N7 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635716-53-9 CAPLUS

CN Acetonitrile, [[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]methylamino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-52-8


CMF C17 H22 N8 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635716-55-1 CAPLUS

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-2-[(1-methylethyl)amino]-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-54-0


CMF C17 H25 N7 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635716-57-3 CAPLUS

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-8-(1-piperazinyl)-2-(2-pyridinylamino)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-56-2

CMF C19 H22 N8 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 635716-59-5 CAPLUS


CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-2-(phenylamino)-8-(1-

piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-58-4


CMF C20 H23 N7 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635716-65-3 CAPLUS

CN Alanine, N-[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-64-2


CMF C17 H23 N7 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635716-67-5 CAPLUS

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-8-(1-piperazinyl)-2-(2-pyridinylmethoxy)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-66-4


CMF C20 H23 N7 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635716-69-7 CAPLUS

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-2-(1-methylethoxy)-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-68-6


CMF C17 H24 N6 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635716-71-1 CAPLUS

CN 6H-Purin-6-one, 7-(2-butynyl)-2-(2-butynyloxy)-1,7-dihydro-1-methyl-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-70-0


CMF C18 H22 N6 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635716-73-3 CAPLUS

CN Acetic acid, [[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]thio]-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-72-2


CMF C17 H22 N6 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635716-75-5 CAPLUS

CN Propanoic acid, 2-[[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]thio]-, ethyl ester, mono(trifluoroacetate)
(9CI) (CA INDEX NAME)

CM 1

CRN 635716-74-4


CMF C19 H26 N6 O3 S



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 635716-77-7 CAPLUS
 CN Propanoic acid, 3-[[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]thio]-, ethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 635716-76-6
 CMF C19 H26 N6 O3 S



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 635716-79-9 CAPLUS
 CN 6H-Purin-6-one, 7-(2-butynyl)-2-(ethylthio)-1,7-dihydro-1-methyl-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 635716-78-8
 CMF C16 H22 N6 O S



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 635716-81-3 CAPLUS

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-2-[(2-hydroxyethyl)thio]-1-methyl-8-(1-piperazinyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-80-2


CMF C16 H22 N6 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635716-86-8 CAPLUS

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-2-(methylthio)-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-85-7


CMF C15 H20 N6 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635716-90-4 CAPLUS

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-2-[(1-methylethyl)thio]-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-89-1


CMF C17 H24 N6 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635716-93-7 CAPLUS

CN 6H-Purin-6-one, 7-(2-butynyl)-2-[(1,1-dimethylethyl)thio]-1,7-dihydro-1-methyl-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-92-6


CMF C18 H26 N6 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635717-00-9 CAPLUS

CN Acetic acid, [[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]thio]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-99-3


CMF C16 H20 N6 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635717-02-1 CAPLUS

CN 6H-Purin-6-one, 7-(2-butynyl)-2-(ethylsulfinyl)-1,7-dihydro-1-methyl-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635717-01-0


CMF C16 H22 N6 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635717-05-4 CAPLUS

CN 6H-Purin-6-one, 7-(2-butynyl)-2-(ethylsulfonyl)-1,7-dihydro-1-methyl-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635717-04-3


CMF C16 H22 N6 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635717-08-7 CAPLUS

CN 1H-Purine-2-carbonitrile, 7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635717-07-6


CMF C15 H17 N7 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 635717-10-1 CAPLUS

CN 1H-Purine-2-carboxamide, 7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 635717-13-4 CAPLUS

CN 1H-Purine-2-carboxylic acid, 7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635717-12-3


CMF C15 H18 N6 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635717-16-7 CAPLUS

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635717-15-6


CMF C14 H18 N6 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 635717-18-9 CAPLUS


CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-2-methoxy-1-(2-phenylethyl)-8-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 635717-20-3 CAPLUS


CN 6H-Purin-6-one, 7-(2-butynyl)-2-ethoxy-1,7-dihydro-1-(2-phenylethyl)-8-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 635717-22-5 CAPLUS


CN Acetic acid, [[7-(2-butynyl)-6,7-dihydro-6-oxo-1-(2-phenylethyl)-8-(1-piperazinyl)-1H-purin-2-yl]thio]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 635717-24-7 CAPLUS


CN Glycine, N-[7-(2-butynyl)-6,7-dihydro-6-oxo-1-(2-phenylethyl)-8-(1-piperazinyl)-1H-purin-2-yl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 635717-25-8 CAPLUS


CN Acetamide, 2-[[7-(2-butynyl)-1,7-dihydro-6-oxo-1-(2-phenylethyl)-8-(1-piperazinyl)-1H-purin-2-yl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 635717-26-9 CAPLUS


CN Glycine, N-[7-(2-butynyl)-6,7-dihydro-6-oxo-1-(2-phenylethyl)-8-(1-piperazinyl)-1H-purin-2-yl]-N-methyl-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 635717-28-1 CAPLUS


CN Acetic acid, [[7-(2-butynyl)-6,7-dihydro-6-oxo-1-(2-phenylethyl)-8-(1-piperazinyl)-1H-purin-2-yl]oxy]-, methyl ester, monohydrochloride (9CI)
(CA INDEX NAME)



● HCl

RN 635717-30-5 CAPLUS


CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-2-(2-hydroxyethoxy)-1-(2-phenylethyl)-8-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 635717-32-7 CAPLUS


CN 6H-Purin-6-one, 7-(2-butynyl)-2-(dimethylamino)-1,7-dihydro-1-(2-phenylethyl)-8-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 635717-35-0 CAPLUS


CN Benzonitrile, 2-[[7-(2-butynyl)-2-(dimethylamino)-6,7-dihydro-6-oxo-8-(1-piperazinyl)-1H-purin-1-yl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 635717-36-1 CAPLUS


CN Acetic acid, [[7-(2-butynyl)-1-[(2-cyanophenyl)methyl]-6,7-dihydro-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]thio]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 635717-37-2 CAPLUS


CN Benzonitrile, 2-[[7-(2-butynyl)-6,7-dihydro-2-methoxy-6-oxo-8-(1-piperazinyl)-1H-purin-1-yl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 635717-39-4 CAPLUS


CN Acetic acid, [[7-(2-butynyl)-1-(cyanomethyl)-6,7-dihydro-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]thio]-, methyl ester, monohydrochloride (9CI)
(CA INDEX NAME)



● HCl

RN 635717-41-8 CAPLUS


CN Acetic acid, [[1,7-di-2-butynyl-6,7-dihydro-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]thio]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 635717-43-0 CAPLUS


CN 1H-Purine-2-carbonitrile, 1,7-di-2-butynyl-6,7-dihydro-6-oxo-8-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 635717-45-2 CAPLUS


CN 6H-Purin-6-one, 1,7-di-2-butynyl-1,7-dihydro-2-methoxy-8-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 635717-46-3 CAPLUS


CN Acetic acid, [[7-(2-butynyl)-6,7-dihydro-6-oxo-8-(1-piperazinyl)-1-(2-propenyl)-1H-purin-2-yl]thio]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 635717-47-4 CAPLUS


CN 1H-Purine-2-carbonitrile, 7-(2-butynyl)-6,7-dihydro-6-oxo-8-(1-piperazinyl)-1-(2-propenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 635717-48-5 CAPLUS


CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-2-methoxy-8-(1-piperazinyl)-1-(2-propenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 635717-49-6 CAPLUS


CN Acetic acid, [[7-(2-butynyl)-6,7-dihydro-1-(2-methoxyethyl)-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]thio]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 635717-50-9 CAPLUS


CN 1H-Purine-2-carbonitrile, 7-(2-butynyl)-6,7-dihydro-1-(2-methoxyethyl)-6-oxo-8-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 635717-51-0 CAPLUS

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-2-methoxy-1-(2-methoxyethyl)-8-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 635717-53-2 CAPLUS

CN 6H-Purin-6-one, 1,7-dihydro-1-methyl-7-(phenylmethyl)-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635717-52-1


CMF C17 H20 N6 O



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 635717-55-4 CAPLUS
 CN 6H-Purin-6-one, 1-ethyl-1,7-dihydro-7-(phenylmethyl)-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 635717-54-3
 CMF C18 H22 N6 O



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 635717-57-6 CAPLUS
 CN 1H-Purine-1-acetic acid, 6,7-dihydro-6-oxo-7-(phenylmethyl)-8-(1-piperazinyl)-, ethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 635717-56-5
 CMF C20 H24 N6 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635717-59-8 CAPLUS

CN 6H-Purin-6-one, 1,7-dihydro-1-(2-methoxyethyl)-7-(phenylmethyl)-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635717-58-7


CMF C19 H24 N6 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635717-61-2 CAPLUS

CN 6H-Purin-6-one, 1,7-dihydro-7-(phenylmethyl)-8-(1-piperazinyl)-1-(2-propynyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635717-60-1


CMF C19 H20 N6 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635717-63-4 CAPLUS

CN 1H-Purine-1-acetonitrile, 6,7-dihydro-6-oxo-7-(phenylmethyl)-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635717-62-3


CMF C18 H19 N7 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 635717-84-9 CAPLUS


CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-2-[(3-hydroxypropyl)thio]-1-methyl-8-(1-piperazinyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

NAME)

CM 1

CRN 635717-83-8


CMF C17 H24 N6 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635717-86-1 CAPLUS

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-2-[(2-hydroxypropyl)thio]-1-methyl-8-(1-piperazinyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 635717-85-0


CMF C17 H24 N6 O2 S



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 635717-90-7 CAPLUS
 CN 6H-Purin-6-one, 7-(2-butynyl)-2-[(2,3-dihydroxypropyl)thio]-1,7-dihydro-1-methyl-8-(1-piperazinyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 635717-89-4
 CMF C17 H24 N6 O3 S



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 635717-93-0 CAPLUS
 CN Propanoic acid, 3-[[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]thio]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 635717-92-9
 CMF C17 H22 N6 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635717-96-3 CAPLUS

CN Propanoic acid, 2-[[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]thio]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635717-95-2


CMF C17 H22 N6 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635717-99-6 CAPLUS

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-2-[(1-methylpropyl)thio]-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635717-98-5


CMF C18 H26 N6 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635718-02-4 CAPLUS

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-8-(1-piperazinyl)-2-(propylthio)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635718-01-3


CMF C17 H24 N6 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635718-08-0 CAPLUS

CN 6H-Purin-6-one, 7-(2-butynyl)-2-(dodecylthio)-1,7-dihydro-1-methyl-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635718-07-9


CMF C26 H42 N6 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635718-10-4 CAPLUS

CN 6H-Purin-6-one, 2-[(2-aminoethyl)thio]-7-(2-butynyl)-1,7-dihydro-1-methyl-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635718-09-1


CMF C16 H23 N7 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 635718-21-7 CAPLUS


CN L-Cysteine, S-[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635718-20-6

CMF C17 H23 N7 O3 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635718-23-9 CAPLUS

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-2-[(2-methylpropyl)thio]-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635718-22-8


CMF C18 H26 N6 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635718-25-1 CAPLUS

CN 6H-Purin-6-one, 7-(2-butynyl)-2-[(1,2-dimethylpropyl)thio]-1,7-dihydro-1-methyl-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635718-24-0


CMF C19 H28 N6 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 635718-33-1 CAPLUS


CN 6H-Purin-6-one, 7-(2-butynyl)-2-[(2-furanylmethyl)thio]-1,7-dihydro-1-

methyl-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635718-32-0


CMF C19 H22 N6 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635718-35-3 CAPLUS

CN Acetamide, 2-[[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]thio]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635718-34-2


CMF C16 H21 N7 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635718-37-5 CAPLUS

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-8-(1-piperazinyl)-2-[(2-thienylmethyl)thio]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635718-36-4


CMF C19 H22 N6 O S2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635718-39-7 CAPLUS

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-8-(1-piperazinyl)-2-[[1-(2-thienyl)ethyl]thio]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635718-38-6


CMF C20 H24 N6 O S2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635718-59-1 CAPLUS

CN Acetamide, N-[2-[[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]thio]ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635718-58-0


CMF C18 H25 N7 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635718-71-7 CAPLUS

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-8-(1-piperazinyl)-2-(2-propenylthio)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635718-70-6


CMF C17 H22 N6 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635718-73-9 CAPLUS

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-2-[[3-(methylthio)phenyl]amino]-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI)
(CA INDEX NAME)

CM 1

CRN 635718-72-8


CMF C21 H25 N7 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 635718-77-3 CAPLUS


CN Propanoic acid, 2-[[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]thio]-2-methyl-, mono(trifluoroacetate) (9CI)

(CA INDEX NAME)

CM 1

CRN 635718-76-2


CMF C18 H24 N6 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635718-79-5 CAPLUS

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-2-[methyl(1-methylethyl)amino]-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635718-78-4


CMF C18 H27 N7 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635719-41-4 CAPLUS

CN 3-Pyridinecarboxamide, 6-[[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635719-40-3

CMF C20 H23 N9 O2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635719-45-8 CAPLUS

CN Benzamide, 2-[[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]amino]-N-(1,1-dimethylethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635719-44-7


CMF C25 H32 N8 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635719-47-0 CAPLUS

CN Benzamide, 2-[[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635719-46-9


CMF C21 H24 N8 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635719-53-8 CAPLUS

CN Benzoic acid, 2-[[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]methylamino]-, mono(trifluoroacetate) (9CI)
(CA INDEX NAME)

CM 1

CRN 635719-52-7


CMF C22 H25 N7 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635719-57-2 CAPLUS

CN Benzenesulfonamide, 2-[[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635719-56-1


CMF C20 H24 N8 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635719-73-2 CAPLUS

CN 1H-Purine-2-acetonitrile, 7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635719-72-1


CMF C16 H19 N7 O



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 635719-77-6 CAPLUS
CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-2-(2-oxopropyl)-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 635719-76-5
CMF C17 H22 N6 O2



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 635719-79-8 CAPLUS
CN 6H-Purin-6-one, 7-(2-butynyl)-2-ethynyl-1,7-dihydro-1-methyl-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 635719-78-7
CMF C16 H18 N6 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 635719-81-2 CAPLUS

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-2-[(1-methylethyl)sulfinyl]-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635719-80-1


CMF C17 H24 N6 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635719-83-4 CAPLUS

CN Acetamide, N-acetyl-N-[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635719-82-3


CMF C18 H23 N7 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635719-85-6 CAPLUS

CN Acetamide, N-[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635719-84-5


CMF C16 H21 N7 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635719-87-8 CAPLUS

CN Acetonitrile, [[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]oxy]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635719-86-7


CMF C16 H19 N7 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635719-89-0 CAPLUS

CN Guanidine, [7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635719-88-9


CMF C15 H21 N9 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635719-91-4 CAPLUS

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-2-(methylthio)-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635719-90-3


CMF C14 H18 N6 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635719-93-6 CAPLUS

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-2-[(1-methylethyl)thio]-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 635719-92-5


CMF C16 H22 N6 O S




CM 2

CRN 76-05-1
CMF C2 H F3 O2RN 635719-95-8 CAPLUS
CN 6H-Purin-6-one, 7-(2-butynyl)-2-[(1,1-dimethylethyl)thio]-1,7-dihydro-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 635719-94-7
CMF C17 H24 N6 O S

CM 2

CRN 76-05-1
CMF C2 H F3 O2RN 635719-97-0 CAPLUS
CN 1H-Purine-2-carbonitrile, 7-(2-butynyl)-6,7-dihydro-6-oxo-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 635719-96-9
CMF C14 H15 N7 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 635720-02-4 CAPLUS

CN 1H-Purine-2-carbonitrile, 7-(2-butynyl)-1-[(2-cyanophenyl)methyl]-6,7-dihydro-6-oxo-8-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 635720-16-0 CAPLUS

CN 1H-Purine-2-carbonitrile, 7-(2-butynyl)-1-[(4-cyanophenyl)methyl]-6,7-dihydro-6-oxo-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635720-15-9


CMF C22 H20 N8 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635720-18-2 CAPLUS

CN Benzonitrile, 4-[[7-(2-butynyl)-6,7-dihydro-2-(methylthio)-6-oxo-8-(1-piperazinyl)-1H-purin-1-yl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635720-17-1


CMF C22 H23 N7 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 635720-22-8 CAPLUS


CN 1H-Purine-2-carbonitrile, 7-(2-butynyl)-1-[(3-cyanophenyl)methyl]-6,7-

dihydro-6-oxo-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635720-21-7


CMF C22 H20 N8 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 635720-25-1 CAPLUS


CN 1H-Purine-2-carbonitrile, 8-(3-amino-1-piperidinyl)-7-(2-butynyl)-1-[(2-cyanophenyl)methyl]-6,7-dihydro-6-oxo-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 635720-26-2 CAPLUS

CN Benzonitrile, 2-[[8-(3-amino-1-piperidinyl)-7-(2-butynyl)-6,7-dihydro-2-methoxy-6-oxo-1H-purin-1-yl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 635720-27-3 CAPLUS
 CN 1H-Purine-2-carbonitrile, 8-(3-amino-1-piperidinyl)-7-(2-butynyl)-6,7-dihydro-6-oxo-1-(2-phenylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 635720-28-4 CAPLUS
 CN 6H-Purine-6-one, 8-(3-amino-1-piperidinyl)-7-(2-butynyl)-1,7-dihydro-2-methoxy-1-(2-phenylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 635720-29-5 CAPLUS
 CN 1H-Purine-2-carbonitrile, 8-(3-amino-1-piperidinyl)-7-(2-butynyl)-1-[(4-cyanophenyl)methyl]-6,7-dihydro-6-oxo-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 635720-30-8 CAPLUS
 CN Benzonitrile, 4-[[8-(3-amino-1-piperidinyl)-7-(2-butynyl)-6,7-dihydro-2-methoxy-6-oxo-1H-purin-1-yl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 635720-34-2 CAPLUS
 CN 1H-Purine-2-carbonitrile, 8-(3-amino-1-piperidinyl)-7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 635720-33-1
 CMF C16 H19 N7 O



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 635720-36-4 CAPLUS
 CN 6H-Purin-6-one, 8-(3-amino-1-piperidiny1)-7-(2-butynyl)-2-[(1,1-dimethylethyl)thio]-1,7-dihydro-1-methyl-, mono(trifluoroacetate) (9CI)
 (CA INDEX NAME)

CM 1

CRN 635720-35-3


CMF C19 H28 N6 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635720-38-6 CAPLUS
 CN 6H-Purin-6-one, 8-(3-amino-1-piperidiny1)-7-(2-butynyl)-1,7-dihydro-2-methoxy-1-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635720-37-5


CMF C16 H22 N6 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635720-40-0 CAPLUS

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-7-(2-butynyl)-2-(diethylamino)-1,7-dihydro-1-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635720-39-7


CMF C19 H29 N7 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 635720-43-3 CAPLUS


CN 1H-Purine-2-carbonitrile, 7-(2-butynyl)-6,7-dihydro-1-methyl-8-[3-(methylamino)-1-piperidinyl]-6-oxo-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 635720-45-5 CAPLUS

CN 1H-Purine-2-carbonitrile, 8-(3-amino-1-pyrrolidinyl)-7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


IT 635717-07-6 635723-88-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation of purinone derivs. as dipeptidylpeptidase IV inhibitors)


RN 635717-07-6 CAPLUS

CN 1H-Purine-2-carbonitrile, 7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 635723-88-5 CAPLUS

CN 1H-Purine-2-carbonitrile, 7-(2-butynyl)-1-[(2-cyanophenyl)methyl]-6,7-dihydro-6-oxo-8-(1-piperazinyl)- (9CI) (CA INDEX NAME)




IT 635722-55-3P 635722-62-2P 635722-67-7P
635722-85-9P 635722-93-9P 635723-71-6P
635723-77-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of purinone derivs. as dipeptidylpeptidase IV inhibitors)


RN 635722-55-3 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-(aminocarbonyl)-7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-1H-purin-8-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 635722-62-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[7-(2-butynyl)-1-[(2-cyanophenyl)methyl]-2-(dimethylamino)-6,7-dihydro-6-oxo-1H-purin-8-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 635722-67-7 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[6,7-dihydro-6-oxo-7-(phenylmethyl)-1H-purin-8-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 635722-85-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[7-(2-butynyl)-2-cyano-1-[(2-cyanophenyl)methyl]-6,7-dihydro-6-oxo-1H-purin-8-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 635722-93-9 CAPLUS



CN Carbamic acid, [1-[7-(2-butynyl)-2-cyano-1-[(2-cyanophenyl)methyl]-6,7-dihydro-6-oxo-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 635723-71-6 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[7-(2-chlorophenyl)-2-(2-ethoxy-2-oxoethoxy)-6,7-dihydro-1-methyl-6-oxo-1H-purin-8-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 635723-77-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[7-(2-butynyl)-2-cyano-6,7-dihydro-1-methyl-6-oxo-1H-purin-8-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L32 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 2

ACCESSION NUMBER: 1995:863353 CAPLUS

DOCUMENT NUMBER: 123:286062

TITLE: Polycyclic guanine derivatives as phosphodiesterase enzyme inhibitors and antihypertensives

INVENTOR(S): Neustadt, Bernard R.; Lindo, Neil A.; McKittrick, Brian A.

PATENT ASSIGNEE(S): Schering Corp., USA


SOURCE: U.S., 32 pp. Cont.-in-part of U.S. Ser. No. 514, 568, abandoned.

IT 140396-39-0P, 2-(trans-2-Hydroxycyclopentylamino)-1-methyl-8-phenyl-7-(phenylmethyl)purin-6-one 140396-40-3P,
2-(trans-2-Hydroxycyclohexylamino)-1-methyl-8-phenyl-7-(phenylmethyl)purin-6-one
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(polycyclic guanine derivs. as phosphodiesterase enzyme inhibitors and antihypertensives)


RN 140396-39-0 CAPLUS

CN 6H-Purin-6-one, 1,7-dihydro-2-[(2-hydroxycyclopentyl)amino]-1-methyl-8-phenyl-7-(phenylmethyl)-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



L32 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 3
 ACCESSION NUMBER: 1992:448192 CAPLUS
 DOCUMENT NUMBER: 117:48192
 TITLE: Studies on purines - part I: Preparation and antimicrobial activity of 2-amino-4-hydroxy-8-(2'-aryl-6'/7'-substituted quinolin-4'-yl)purines and their Mannich bases
 AUTHOR(S): Lakhani, R. R.; Parikh, A. R.
 CORPORATE SOURCE: Dep. Chem., Saurashtra Univ., Rajkot, 360005, India
 SOURCE: Acta Ciencia Indica, Chemistry (1991), 17C(1), 47-54
 CODEN: ACICDV; ISSN: 0253-7338
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 ED Entered STN: 08 Aug 1992
 GI




AB The title compds. I (R = HO, MeO, R1, R2 = H, MeO, Me, O2N, Cl) were prepared by cyclocondensation of quinolinecarboxylic acids with 2,4,5-triamino-6-hydroxypyrimidine followed by Mannich reaction with Et2NH. The prepared compds. were tested for bactericidal activity.
 IT 141853-43-2P 141853-44-3P 141853-45-4P
 141853-46-5P 141853-47-6P 141853-48-7P
 141853-49-8P 141853-50-1P 141853-51-2P
 141853-52-3P 141853-53-4P 141853-54-5P
 141853-55-6P 141853-56-7P 141853-57-8P
 141853-58-9P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
 RN 141853-43-2 CAPLUS
 CN 6H-Purin-6-one, 2-amino-7-[(diethylamino)methyl]-1,7-dihydro-8-[2-(4-hydroxyphenyl)-7-methoxy-4-quinoliny]- (9CI) (CA INDEX NAME)




RN 141853-44-3 CAPLUS

CN 6H-Purin-6-one, 2-amino-7-[(diethylamino)methyl]-1,7-dihydro-8-[2-(4-hydroxyphenyl)-6-methoxy-4-quinolinyl]- (9CI) (CA INDEX NAME)




RN 141853-45-4 CAPLUS

CN 6H-Purin-6-one, 2-amino-7-[(diethylamino)methyl]-1,7-dihydro-8-[2-(4-hydroxyphenyl)-7-methyl-4-quinolinyl]- (9CI) (CA INDEX NAME)




RN 141853-46-5 CAPLUS

CN 6H-Purin-6-one, 2-amino-7-[(diethylamino)methyl]-1,7-dihydro-8-[2-(4-hydroxyphenyl)-6-methyl-4-quinolinyl]- (9CI) (CA INDEX NAME)




RN 141853-47-6 CAPLUS

CN 6H-Purin-6-one, 2-amino-7-[(diethylamino)methyl]-1,7-dihydro-8-[2-(4-hydroxyphenyl)-7-nitro-4-quinolinyl]- (9CI) (CA INDEX NAME)




RN 141853-48-7 CAPLUS

CN 6H-Purin-6-one, 2-amino-7-[(diethylamino)methyl]-1,7-dihydro-8-[2-(4-hydroxyphenyl)-6-nitro-4-quinolinyl]- (9CI) (CA INDEX NAME)




RN 141853-49-8 CAPLUS

CN 6H-Purin-6-one, 2-amino-8-[7-chloro-2-(4-hydroxyphenyl)-4-quinolinyl]-7-[(diethylamino)methyl]-1,7-dihydro- (9CI) (CA INDEX NAME)




RN 141853-50-1 CAPLUS

CN 6H-Purin-6-one, 2-amino-8-[6-chloro-2-(4-hydroxyphenyl)-4-quinolinyl]-7-[(diethylamino)methyl]-1,7-dihydro- (9CI) (CA INDEX NAME)




RN 141853-51-2 CAPLUS

CN 6H-Purin-6-one, 2-amino-7-[(diethylamino)methyl]-1,7-dihydro-8-[7-methoxy-2-(4-methoxyphenyl)-4-quinolinyl]- (9CI) (CA INDEX NAME)




RN 141853-52-3 CAPLUS

CN 6H-Purin-6-one, 2-amino-7-[(diethylamino)methyl]-1,7-dihydro-8-[6-methoxy-2-(4-methoxyphenyl)-4-quinolinyl]- (9CI) (CA INDEX NAME)




RN 141853-53-4 CAPLUS

CN 6H-Purin-6-one, 2-amino-7-[(diethylamino)methyl]-1,7-dihydro-8-[2-(4-methoxyphenyl)-7-methyl-4-quinolinyl]- (9CI) (CA INDEX NAME)




RN 141853-54-5 CAPLUS

CN 6H-Purin-6-one, 2-amino-7-[(diethylamino)methyl]-1,7-dihydro-8-[2-(4-methoxyphenyl)-6-methyl-4-quinolinyl]- (9CI) (CA INDEX NAME)




RN 141853-55-6 CAPLUS

CN 6H-Purin-6-one, 2-amino-7-[(diethylamino)methyl]-1,7-dihydro-8-[2-(4-methoxyphenyl)-7-nitro-4-quinolinyl]- (9CI) (CA INDEX NAME)




RN 141853-56-7 CAPLUS

CN 6H-Purin-6-one, 2-amino-7-[(diethylamino)methyl]-1,7-dihydro-8-[2-(4-methoxyphenyl)-6-nitro-4-quinolinyl]- (9CI) (CA INDEX NAME)




RN 141853-57-8 CAPLUS

CN 6H-Purin-6-one, 2-amino-8-[7-chloro-2-(4-methoxyphenyl)-4-quinolinyl]-7-[(diethylamino)methyl]-1,7-dihydro- (9CI) (CA INDEX NAME)



RN 141853-58-9 CAPLUS



CN 6H-Purin-6-one, 2-amino-8-[6-chloro-2-(4-methoxyphenyl)-4-quinolinyl]-7-[(diethylamino)methyl]-1,7-dihydro- (9CI) (CA INDEX NAME)



L32 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 4
 ACCESSION NUMBER: 1991:608009 CAPLUS
 DOCUMENT NUMBER: 115:208009
 TITLE: Preparation of 2-aminopyrimidinones as antihistaminics and antiserotonergics
 INVENTOR(S): Janssens, Frans E.; Kennis, Ludo E. J.; Sommen, Francois M.; Dierckx, Ann C. J.
 PATENT ASSIGNEE(S): Janssen Pharmaceutica N. V., Belg.
 SOURCE: Eur. Pat. Appl., 30 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 378254	A2	19900718	EP 1990-200004	19900103
EP 378254	A3	19910109		
EP 378254	B1	19940622		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL				
US 5008268	A	19910416	US 1989-456391	19891226
ES 2058749	T3	19941101	ES 1990-200004	19900103
CA 2007198	AA	19900709	CA 1990-2007198	19900105
FI 9000084	A	19900710	FI 1990-84	19900108
FI 94526	B	19950615		
FI 94526	C	19950925		
NO 9000070	A	19900710	NO 1990-70	19900108
NO 172645	B	19930510		
NO 172645	C	19930818		
AU 9047780	A1	19900712	AU 1990-47780	19900108
AU 622509	B2	19920409		
HU 53364	A2	19901028	HU 1990-63	19900108
HU 206350	B	19921028		
ZA 9000120	A	19910925	ZA 1990-120	19900108
SU 1825364	A3	19930630	SU 1990-4742861	19900108
CN 1044099	A	19900725	CN 1990-100077	19900109
CN 1030452	B	19951206		
JP 02233678	A2	19900917	JP 1990-2414	19900109
PRIORITY APPLN. INFO.:			GB 1989-380	A 19890109
OTHER SOURCE(S):	MARPAT 115:208009			
ED Entered STN: 15 Nov 1991				

GI




AB The title compds. [I; X1X2X3X4 = (substituted) CH:CHCH:CH, N:CHCH:CH, CH:NCH:CH, CH:CHN:CH, CH:CHCH:N, N:CHN:CH, CH:NCH:N; R1 = H, alkyl, cycloalkyl, arylalkyl, etc.; R2, R3, R6 = H, alkyl; n = 0-2; R4 = H, (substituted) alkyl; R5 = H, alkyl, alkylaminocarbonyl, arylaminocarbonyl; R5R6 = (alkyl-substituted) CH2CH2, CH2CH2CH2, CH:CH, CH:N, N:CH, N:CHCH2; Z = alkylene; Z1 = CH2, O, S, SO, SO2, imino], were prepared Thus, 1-[(4-fluorophenyl)methyl]-2-(4-piperidinylmethyl)-1H-benzimidazole, 4-methyl-2-pentanone, and Na2CO3 were refluxed 42 h to give 51.2% title compound II which had an ED50 of 0.005 mg/kg in rats for reduction of tryptamine-induced hyperemia.

IT **131264-36-3P**


RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as antihistaminic and antiserotonergic)

RN 131264-36-3 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyrimidin-5(1H)-one, 6-[2-[4-[[7-[(4-fluorophenyl)methyl]-6,7-dihydro-6-oxo-1H-purin-8-yl]amino]-1-piperidinyl]ethyl]-1,3,7-trimethyl- (9CI) (CA INDEX NAME)



L32 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 5
ACCESSION NUMBER: 1988:217553 CAPLUS
DOCUMENT NUMBER: 108:217553
TITLE: Synthesis and identification of benzo[a]pyrene-guanine
nucleoside adducts formed by electrochemical oxidation
and by horseradish peroxidase catalyzed reaction of
benzo[a]pyrene with DNA
AUTHOR(S): Rogan, E. G.; Cavalieri, E. L.; Tibbels, S. R.;
Cremonesi, P.; Warner, C. D.; Nagel, D. L.; Tomer, K.
B.; Cerny, R. L.; Gross, M. L.
CORPORATE SOURCE: Dep. Pharm. Sci., Univ. Nebraska Med. Cent., Omaha,
NE, 68105-1065, USA
SOURCE: Journal of the American Chemical Society (1988),
110(12), 4023-9
CODEN: JACSAT; ISSN: 0002-7863
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 108:217553
ED Entered STN: 24 Jun 1988
GI



AB The synthesis of adducts by anodic oxidation of benzo[a]pyrene (BP) in the presence of deoxyguanosine (dG) or guanosine (G) is reported. By using ¹H and 2-dimensional NMR spectroscopy as well as fast atom bombardment and collisionally activated decomposition (CAD) mass spectrometry, adducts were identified as BP bound at C-6-C-8 of guanine (Gua), dG, and G and to N-7 of Gua. Loss of deoxyribose from the N-7 adduct was anticipated, but it was unexpectedly found that .apprx.30% of the C-8 adduct with dG lost the deoxyribose moiety. The C-8 adduct of G almost entirely retained the ribose moiety. These compds. were used as markers for HPLC to identify adducts formed in the horseradish peroxidase-catalyzed binding of BP to DNA. By use of HPLC in 2 solvent systems, adducts were identified in the supernatant fraction obtained after EtOH precipitation of the DNA and in an enzymic digest of the DNA. The supernatant, containing adducts lost by depurination, afforded 95% of the N-7 adduct and .apprx.50% of the C-8 adduct. The major adduct identified in the DNA digest was the C-8 of dG (I). The structure of the N-7 adduct in the supernatant was confirmed by CAD mass spectrometry. Thus, horseradish peroxidase catalyzes binding of BP to DNA by 1-electron oxidation


IT 114378-33-5

RL: FORM (Formation, nonpreparative)

(formation of, from benzopyrene under oxidizing conditions)

RN 114378-33-5 CAPLUS

CN 6H-Purin-6-one, 2-amino-7,8-bis(benzo[a]pyren-6-yl)-1,7-dihydro- (9CI)
(CA INDEX NAME)



L32 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:965251 CAPLUS

DOCUMENT NUMBER: 141:410949

TITLE: Preparation of fused imidazole derivatives as DPP-IV inhibitors

INVENTOR(S): Nakahira, Hiroyuki; Hochigai, Hitoshi

PATENT ASSIGNEE(S): Sumitomo Pharmaceuticals Co., Ltd., Japan

SOURCE: PCT Int. Appl., 335 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004096806	A1	20041111	WO 2004-JP6104	20040427
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.:	JP 2003-125715	A 20030430
	JP 2003-352423	A 20031010

OTHER SOURCE(S): MARPAT 141:410949

ED Entered STN: 12 Nov 2004

GI



AB The compds. I [R1 represents hydrogen, optionally substituted alkyl, etc.; R2 represents hydrogen, optionally substituted alkyl, optionally substituted aryl, etc.; R3 represents hydrogen, optionally substituted aryl, etc.; and -Y-NH2 represents, e.g., a group represented by Q1 (A is (CH2)_m; m is 0, 1, or 2; and R4 is absent, or one or two R4's are present, the R4's each independently representing optionally substituted alkyl, etc.).] are prepared Reaction of 1-methyl-2-dimethylamino-8-bromo-7-benzyl-1,7-dihydro-6H-purin-6-one with (R)-3-aminopiperidine 2HCl salt in ethanol containing diisopropylethylamine at 110°C for 100 h gave, after workup, 2-dimethylamino-8-[(3R)-3-aminopiperidin-1-yl]-7-benzyl-1-methyl-1,7-dihydro-6H-purin-6-one. Compds. of this invention in vitro showed IC50 values of 2 nM to 104 nM against human DPP-IV (dipeptidyl peptidase IV).

IT 791074-69-6P 791074-71-0P 791074-73-2P
791074-75-4P 791074-77-6P 791074-78-7P
791074-79-8P 791074-80-1P 791074-82-3P
791074-85-6P 791074-87-8P 791074-89-0P
791074-91-4P 791074-92-5P 791074-94-7P
791074-97-0P 791076-41-0P 791076-42-1P
791076-43-2P 791076-44-3P 791076-47-6P
791076-48-7P 791076-49-8P 791076-50-1P
791077-07-1P 791077-08-2P 791077-25-3P
791077-26-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of fused imidazole derivs. as DPP-IV inhibitors)

RN 791074-69-6 CAPLUS

CN 6H-Purin-6-one, 8-[(3R)-3-amino-1-piperidiny]-7-[(2-bromophenyl)methyl]-1,7-dihydro-1-methyl-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 791074-71-0 CAPLUS

CN Benzonitrile, 2-[[8-[(3R)-3-amino-1-piperidinyl]-1,6-dihydro-1-methyl-6-oxo-2-(trifluoromethyl)-7H-purin-7-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 791074-73-2 CAPLUS

CN 6H-Purin-6-one, 8-[(3R)-3-amino-1-piperidinyl]-7-[(2-bromophenyl)methyl]-1,7-dihydro-2-methyl-1-(2-oxo-2-phenylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 791074-75-4 CAPLUS

CN 6H-Purin-6-one, 8-[(3R)-3-amino-1-piperidinyl]-7-[(2-bromophenyl)methyl]-1,7-dihydro-1,2-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 791074-77-6 CAPLUS

CN 6H-Purin-6-one, 8-[(3R)-3-amino-1-piperidinyl]-7-[(2-bromophenyl)methyl]-1,7-dihydro-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 791074-78-7 CAPLUS

CN 6H-Purin-6-one, 8-[(3R)-3-amino-1-piperidinyl]-7-[(2-chlorophenyl)methyl]-1,7-dihydro-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 791074-79-8 CAPLUS

CN 6H-Purin-6-one, 8-[(3R)-3-amino-1-piperidinyl]-7-[(2-bromophenyl)methyl]-1,7-dihydro-1-(2-oxo-2-phenylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 791074-80-1 CAPLUS

CN 6H-Purin-6-one, 8-[[[(1R,2S)-2-aminocyclohexyl]amino]-7-[(2-bromophenyl)methyl]-1,7-dihydro-1-(2-oxo-2-phenylethyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry..



RN 791074-82-3 CAPLUS

CN 6H-Purin-6-one, 8-[[[(1R,2S)-2-aminocyclohexyl]amino]-7-[(2-bromophenyl)methyl]-1,7-dihydro-1-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 791074-85-6 CAPLUS


CN 6H-Purin-6-one, 8-[(3R)-3-amino-1-piperidinyl]-7-[(5-fluoro-2-methylphenyl)methyl]-1,7-dihydro-1-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 791074-84-5

CMF C19 H23 F N6 O


Absolute stereochemistry.



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 791074-87-8 CAPLUS

CN 6H-Purin-6-one, 2-amino-8-(3-amino-1-piperidinyl)-1,7-dihydro-7-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 791074-89-0 CAPLUS


CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-2-ethoxy-1,7-dihydro-7-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 791074-91-4 CAPLUS

CN 6H-Purin-6-one, 8-[(3R)-3-amino-1-piperidinyl]-2-(dimethylamino)-1,7-dihydro-1-methyl-7-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 791074-92-5 CAPLUS

CN 6H-Purin-6-one, 8-[(3R)-3-amino-1-piperidinyl]-7-[(2-chlorophenyl)methyl]-2-(dimethylamino)-1,7-dihydro-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 791074-94-7 CAPLUS

CN 6H-Purin-6-one, 2-amino-8-[(3R)-3-amino-1-piperidinyl]-7-[(2-chlorophenyl)methyl]-1,7-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 791074-97-0 CAPLUS

CN 6H-Purin-6-one, 8-[(3R)-3-amino-1-piperidinyl]-7-[(2-chlorophenyl)methyl]-1,7-dihydro-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 791076-41-0 CAPLUS

CN 1H-Purine-2-carboxylic acid, 8-[(3R)-3-amino-1-piperidinyl]-7-[(2-chlorophenyl)methyl]-6,7-dihydro-6-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 791076-42-1 CAPLUS

CN 1H-Purine-1-acetamide, 8-[(3R)-3-amino-1-piperidinyl]-7-[(2-chlorophenyl)methyl]-2-cyano-6,7-dihydro-6-oxo-N-2-pyridinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 791076-43-2 CAPLUS

CN 1H-Purine-1-acetic acid, 2-(aminocarbonyl)-8-[(3R)-3-amino-1-piperidinyl]-7-[(2-chlorophenyl)methyl]-6,7-dihydro-6-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 791076-44-3 CAPLUS

CN 6H-Purin-6-one, 8-[(3R)-3-amino-1-piperidinyl]-2-benzoyl-7-[(2-chlorophenyl)methyl]-1,7-dihydro-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 791076-47-6 CAPLUS

CN 1H-Purine-2-carbonitrile, 8-[(3R)-3-amino-1-piperidinyl]-7-[(2-chlorophenyl)methyl]-6,7-dihydro-1-methyl-6-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 791076-48-7 CAPLUS

CN 6H-Purin-6-one, 2-acetyl-8-[(3R)-3-amino-1-piperidinyl]-7-[(2-chlorophenyl)methyl]-1,7-dihydro-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 791076-49-8 CAPLUS

CN 6H-Purin-6-one, 8-[(3R)-3-amino-1-piperidinyl]-7-[(2-chlorophenyl)methyl]-1,7-dihydro-1-methyl-2-(methylthio)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 791076-50-1 CAPLUS

CN 6H-Purin-6-one, 8-[(3R)-3-amino-1-piperidinyl]-7-[(2-chlorophenyl)methyl]-1,7-dihydro-1-methyl-2-(methylsulfonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 791077-07-1 CAPLUS

CN 6H-Purin-6-one, 8-[(3R)-3-amino-1-piperidinyl]-7-[(2-chlorophenyl)methyl]-1,7-dihydro-1-methyl-2-(phenylamino)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 791077-08-2 CAPLUS

CN 6H-Purin-6-one, 8-[(3R)-3-amino-1-piperidinyl]-7-[(2-chlorophenyl)methyl]-1,7-dihydro-1-methyl-2-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 791077-25-3 CAPLUS

CN 1H-Purine-2-carboxylic acid, 8-[(3R)-3-amino-1-piperidinyl]-7-[(2-chlorophenyl)methyl]-6,7-dihydro-6-oxo-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 791077-26-4 CAPLUS

CN 1H-Purine-2-carboxylic acid, 8-[(3R)-3-amino-1-piperidinyl]-7-[(2-chlorophenyl)methyl]-6,7-dihydro-6-oxo-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 791075-05-3P 791075-07-5P 791075-92-8P
 791075-93-9P 791075-94-0P 791075-95-1P
 791075-98-4P 791075-99-5P 791076-00-1P
 791076-01-2P 791076-02-3P 791076-03-4P
 791076-04-5P 791076-05-6P 791076-10-3P
 791076-13-6P 791076-14-7P 791076-15-8P
 791076-16-9P 791076-19-2P 791076-20-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of fused imidazole derivs. as DPP-IV inhibitors)

RN 791075-05-3 CAPLUS

CN Carbamic acid, [(3R)-1-[7-[(2-bromophenyl)methyl]-6,7-dihydro-1-methyl-6-oxo-2-(trifluoromethyl)-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 791075-07-5 CAPLUS

CN Carbamic acid, [(3R)-1-[7-[(2-bromophenyl)methyl]-6,7-dihydro-1,2-dimethyl-6-oxo-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 791075-92-8 CAPLUS

CN 1H-Purine-2-carboxylic acid, 7-[(2-chlorophenyl)methyl]-8-[(3R)-3-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-piperidinyl]-6,7-dihydro-6-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 791075-93-9 CAPLUS

CN Carbamic acid, [(3R)-1-[7-[(2-chlorophenyl)methyl]-2-cyano-6,7-dihydro-6-oxo-1-[2-oxo-2-(2-pyridinylamino)ethyl]-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 791075-94-0 CAPLUS

CN 1H-Purine-1-acetic acid, 7-[(2-chlorophenyl)methyl]-2-cyano-8-[(3R)-3-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-piperidinyl]-6,7-dihydro-6-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 791075-95-1 CAPLUS

CN Carbamic acid, [(3R)-1-[2-benzoyl-7-[(2-chlorophenyl)methyl]-6,7-dihydro-1-methyl-6-oxo-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 791075-98-4 CAPLUS

CN Carbamic acid, [(3R)-1-[7-[(2-chlorophenyl)methyl]-2-cyano-6,7-dihydro-1-methyl-6-oxo-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 791075-99-5 CAPLUS

CN Carbamic acid, [(3R)-1-[2-acetyl-7-[(2-chlorophenyl)methyl]-6,7-dihydro-1-methyl-6-oxo-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 791076-00-1 CAPLUS

CN Carbamic acid, [(3R)-1-[7-[(2-chlorophenyl)methyl]-6,7-dihydro-1-methyl-2-(methylthio)-6-oxo-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 791076-01-2 CAPLUS

CN Carbamic acid, [(3R)-1-[6,7-dihydro-1-methyl-7-[(2-methylphenyl)methyl]-2-(methylthio)-6-oxo-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 791076-02-3 CAPLUS

CN Carbamic acid, [(3R)-1-[7-[(2-chloro-5-fluorophenyl)methyl]-6,7-dihydro-1-methyl-2-(methylthio)-6-oxo-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 791076-03-4 CAPLUS

CN Carbamic acid, [(3R)-1-[7-[(2-chlorophenyl)methyl]-6,7-dihydro-1-methyl-2-(methylsulfonyl)-6-oxo-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 791076-04-5 CAPLUS

CN Carbamic acid, [(3R)-1-[6,7-dihydro-1-methyl-7-[(2-methylphenyl)methyl]-2-(methylsulfonyl)-6-oxo-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 791076-05-6 CAPLUS

CN Carbamic acid, [(3R)-1-[7-[(2-chloro-5-fluorophenyl)methyl]-6,7-dihydro-1-methyl-2-(methylsulfonyl)-6-oxo-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 791076-10-3 CAPLUS

CN Carbamic acid, [(3R)-1-[7-[(2-chlorophenyl)methyl]-6,7-dihydro-1-methyl-6-oxo-2-(phenylamino)-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 791076-13-6 CAPLUS

CN 1H-Purine-1-acetic acid, 7-[(2-chlorophenyl)methyl]-8-[(3R)-3-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-piperidinyl]-6,7-dihydro-2-(methylsulfonyl)-6-oxo-, 2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 791076-14-7 CAPLUS

CN 1H-Purine-1-acetic acid, 7-[(2-chlorophenyl)methyl]-8-[(3R)-3-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-piperidinyl]-6,7-dihydro-2-(methylthio)-6-oxo-, 2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 791076-15-8 CAPLUS

CN 1H-Purine-1-acetic acid, 7-[(2-chlorophenyl)methyl]-8-[(3R)-3-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-piperidinyl]-6,7-dihydro-2-(methylthio)-6-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 791076-16-9 CAPLUS

CN 1H-Purine-1-acetic acid, 7-[(2-chlorophenyl)methyl]-8-[(3R)-3-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-piperidiny]]-6,7-dihydro-2-(methylthio)-6-oxo-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 791076-19-2 CAPLUS

CN 1H-Purine-2-carboxylic acid, 7-[(2-chlorophenyl)methyl]-8-[(3R)-3-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-piperidiny]]-6,7-dihydro-6-oxo-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 791076-20-5 CAPLUS

CN 1H-Purine-1-acetic acid, 7-[(2-chlorophenyl)methyl]-2-cyano-8-[(3R)-3-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-piperidiny]]-6,7-dihydro-6-oxo-, 2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L32 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:287778 CAPLUS

DOCUMENT NUMBER: 140:303701

TITLE: Preparation of piperazine derivatives as dipeptidyl peptidase IV inhibitors

INVENTOR(S): Yasuda, Nobuyuki; Yamazaki, Kazuto

PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan

SOURCE: PCT Int. Appl., 302 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004028524	A1	20040408	WO 2003-JP12075	20030922
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: JP 2002-280137 A 20020926
JP 2003-117927 A 20030423

OTHER SOURCE(S): MARPAT 140:303701

ED Entered STN: 08 Apr 2004

GI



AB The title compds. I and II [wherein ring T = (un)substituted heterocyclyl; X = (un)substituted alkyl, alkenyl, alkynyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; Z1 and Z2 = independently N or (un)substituted CH; R1 and R2 = independently H, (un)substituted alkyl, etc.] or salts or hydrates thereof are prepared as dipeptidyl peptidase (DPP) IV inhibitors in combination with biguanide. For example, the compound III•HCl was prepared in a multi-step synthesis. III•HCl showed inhibitory activity with IC50 of 0.472 nM against DPP IV in pig. I are useful for the treatment of diabetes, obesity, hyperlipidemia, gastrointestinal disturbance, etc.

IT 635715-41-2P 635715-48-9P 635715-58-1P
 635715-62-7P 635715-63-8P 635715-64-9P
 635715-66-1P 635715-81-0P 635715-95-6P
 635716-19-7P 635716-65-3P 635716-73-3P
 635716-90-4P 635717-00-9P 635717-07-6P
 635717-08-7P 635717-10-1P 635717-18-9P
 635717-22-5P 635717-35-0P 635717-37-2P
 635717-53-2P 635717-93-0P 635718-02-4P
 635718-39-7P 635720-02-4P 635720-25-1P
 635720-26-2P 635723-88-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of piperazine derivs. as dipeptidyl peptidase IV inhibitors)


RN 635715-41-2 CAPLUS

CN Acetic acid, [[7-(2-chlorophenyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]oxy]-, ethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635715-40-1


CMF C20 H23 Cl N6 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635715-48-9 CAPLUS

CN Benzeneacetic acid, α -[[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]oxy]-, methyl ester, mono(trifluoroacetate)
(9CI) (CA INDEX NAME)

CM 1

CRN 635715-47-8


CMF C23 H26 N6 O4



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 635715-58-1 CAPLUS

CN Propanoic acid, 2-[[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 635715-62-7 CAPLUS

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-2-methoxy-1-methyl-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635715-61-6


CMF C15 H20 N6 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 635715-63-8 CAPLUS

CN 6H-Purin-6-one, 7-(2-butynyl)-2-ethoxy-1,7-dihydro-1-methyl-8-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 635715-64-9 CAPLUS

CN Acetic acid, [[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 635715-66-1 CAPLUS

CN Acetic acid, [[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]oxy]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635715-65-0


CMF C16 H20 N6 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 635715-81-0 CAPLUS


CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1,2-dimethyl-8-(1-piperazinyl)-,

mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635715-80-9


CMF C15 H20 N6 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635715-95-6 .CAPLUS

CN 6H-Purin-6-one, 7-(2-butynyl)-2-(dimethylamino)-1,7-dihydro-1-methyl-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635715-94-5


CMF C16 H23 N7 O



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 635716-19-7 CAPLUS
 CN 6H-Purin-6-one, 7-(2-butynyl)-2-[(2-ethoxyethyl)amino]-1,7-dihydro-1-methyl-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 635716-18-6
 CMF C18 H27 N7 O2



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 635716-65-3 CAPLUS
 CN Alanine, N-[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 635716-64-2
 CMF C17 H23 N7 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635716-73-3 CAPLUS

CN Acetic acid, [[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]thio]-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-72-2


CMF C17 H22 N6 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635716-90-4 CAPLUS

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-2-[(1-methylethyl)thio]-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-89-1


CMF C17 H24 N6 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635717-00-9 CAPLUS

CN Acetic acid, [[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]thio]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-99-3


CMF C16 H20 N6 O3 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 635717-07-6 CAPLUS

CN 1H-Purine-2-carbonitrile, 7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 635717-08-7 CAPLUS

CN 1H-Purine-2-carbonitrile, 7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635717-07-6


CMF C15 H17 N7 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 635717-10-1 CAPLUS


CN 1H-Purine-2-carboxamide, 7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 635717-18-9 CAPLUS

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-2-methoxy-1-(2-phenylethyl)-8-(1-


piperaziny)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 635717-22-5 CAPLUS


CN Acetic acid, [[7-(2-butynyl)-6,7-dihydro-6-oxo-1-(2-phenylethyl)-8-(1-piperazinyl)-1H-purin-2-yl]thio]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 635717-35-0 CAPLUS


CN Benzonitrile, 2-[[7-(2-butynyl)-2-(dimethylamino)-6,7-dihydro-6-oxo-8-(1-piperazinyl)-1H-purin-1-yl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 635717-37-2 CAPLUS

CN Benzonitrile, 2-[[7-(2-butynyl)-6,7-dihydro-2-methoxy-6-oxo-8-(1-piperazinyl)-1H-purin-1-yl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 635717-53-2 CAPLUS

CN 6H-Purin-6-one, 1,7-dihydro-1-methyl-7-(phenylmethyl)-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635717-52-1


CMF C17 H20 N6 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635717-93-0 CAPLUS

CN Propanoic acid, 3-[[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]thio]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635717-92-9


CMF C17 H22 N6 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635718-02-4 CAPLUS

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-8-(1-piperazinyl)-2-(propylthio)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635718-01-3


CMF C17 H24 N6 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635718-39-7 CAPLUS

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-8-(1-piperazinyl)-2-[[1-(2-thienyl)ethyl]thio]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635718-38-6


CMF C20 H24 N6 O S2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 635720-02-4 CAPLUS


CN 1H-Purine-2-carbonitrile, 7-(2-butynyl)-1-[(2-cyanophenyl)methyl]-6,7-dihydro-6-oxo-8-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 635720-25-1 CAPLUS


CN 1H-Purine-2-carbonitrile, 8-(3-amino-1-piperidinyl)-7-(2-butynyl)-1-[(2-cyanophenyl)methyl]-6,7-dihydro-6-oxo-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 635720-26-2 CAPLUS


CN Benzonitrile, 2-[[8-(3-amino-1-piperidiny)-7-(2-butynyl)-6,7-dihydro-2-methoxy-6-oxo-1H-purin-1-yl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 635723-88-5 CAPLUS

CN 1H-Purine-2-carbonitrile, 7-(2-butynyl)-1-[(2-cyanophenyl)methyl]-6,7-dihydro-6-oxo-8-(1-piperazinyl)- (9CI) (CA INDEX NAME)


IT 635715-40-1P 635722-55-3P 635722-62-2P
635722-67-7P 635722-85-9P 635722-93-9P
635723-77-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of piperazine derivs. as dipeptidyl peptidase IV inhibitors)


RN 635715-40-1 CAPLUS

CN Acetic acid, [[7-(2-chlorophenyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 635722-55-3 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-(aminocarbonyl)-7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-1H-purin-8-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 635722-62-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[7-(2-butynyl)-1-[(2-cyanophenyl)methyl]-2-(dimethylamino)-6,7-dihydro-6-oxo-1H-purin-8-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 635722-67-7 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[6,7-dihydro-6-oxo-7-(phenylmethyl)-1H-purin-8-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 635722-85-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[7-(2-butynyl)-2-cyano-1-[(2-cyanophenyl)methyl]-6,7-dihydro-6-oxo-1H-purin-8-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 635722-93-9 CAPLUS

CN Carbamic acid, [1-[7-(2-butynyl)-2-cyano-1-[(2-cyanophenyl)methyl]-6,7-dihydro-6-oxo-1H-purin-8-yl]-3-piperidinyll]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 635723-77-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[7-(2-butynyl)-2-cyano-6,7-dihydro-1-methyl-6-oxo-1H-purin-8-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L32 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:177910 CAPLUS

DOCUMENT NUMBER: 140:235734

TITLE: Preparation of purine derivatives as dipeptidylpeptidase IV (DPP-IV) inhibitors.

INVENTOR(S): Maier, Roland; Himmelsbach, Frank; Eckhardt, Matthias; Langkopf, Elke; Mark, Michael; Lotz, Ralf

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G., Germany

SOURCE: Ger. Offen., 38 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

This work

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10238477	A1	20040304	DE 2002-10238477	20020822
US 2004122228	A1	20040624	US 2003-634047	20030804
WO 2004018469	A1	20040304	WO 2003-EP9100	20030816
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.:


DE 2002-10238477 A 20020822

US 2002-408021P P 20020904

OTHER SOURCE(S): MARPAT 140:235734

ED Entered STN: 04 Mar 2004

GI



AB Title compds. [I; R1 = H, (substituted) alkyl, alkenyl, alkynyl, etc.; R2 = H, (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, Ph, heteroaryl, etc.; R3 = (substituted) alkyl, alkenyl, alkynyl, aryl, aralkyl; R4 = substituted azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, hexahydroazepin-1-yl, 3-aminopiperidin-1-yl, etc.], were prepared Thus, [1-(7-benzyl-2-benzylamino-1-methyl-6-oxo-6,7-dihydro-1H-purin-8-yl)piperidin-3-yl]carbamic acid tert-Bu ester (preparation given) was stirred 2 h with CF₃CO₂H in CH₂Cl₂ to give 73.1% 8-(3-aminopiperidin-1-yl)-7-benzyl-2-benzylamino-1-methyl-1,7-dihydropurin-6-one trifluoroacetate. This inhibited DPP-IV with IC₅₀ = 11 nM.

IT 666702-26-7P 666702-31-4P 666702-35-8P

666702-40-5P 666702-45-0P 666702-50-7P

666702-56-3P 666702-63-2P 666702-67-6P

666702-70-1P 666702-73-4P 666702-77-8P

666702-82-5P 666702-86-9P 666702-89-2P

666702-91-6P 666702-94-9P 666702-97-2P

666703-02-2P 666703-05-5P 666703-09-9P

666703-11-3P 666703-14-6P 666703-17-9P

666703-20-4P 666703-21-5P 666703-25-9P

666703-27-1P 666703-29-3P 666703-31-7P

666703-33-9P 666703-35-1P 666703-37-3P

666703-41-9P 666703-45-3P 666703-47-5P

666703-50-0P 666703-52-2P 666703-54-4P


666703-56-6P 666704-19-4P 666704-74-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of purine derivs. as dipeptidylpeptidase IV inhibitors)


RN 666702-26-7 CAPLUS

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-1-methyl-7-(phenylmethyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 666702-31-4 CAPLUS


CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-2-[[4-(4-fluorophenyl)methyl]amino]-1,7-dihydro-1-methyl-7-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 666702-35-8 CAPLUS


CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-1-methyl-2-[(2-

phenylethyl)amino]-7-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 666702-40-5 CAPLUS

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-1-methyl-2-[(1-methylethyl)amino]-7-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 666702-45-0 CAPLUS

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-1-methyl-2-(methylethylamino)-7-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 666702-50-7 CAPLUS

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-2-(cyclohexylamino)-1-methyl-7-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 666702-56-3 CAPLUS

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-2-[(cyclohexylmethyl)amino]-1,7-dihydro-1-methyl-7-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 666702-63-2 CAPLUS

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-2-(dimethylamino)-1,7-dihydro-1-methyl-7-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 666702-67-6 CAPLUS

CN 6H-Purin-6-one, 2-amino-8-(3-amino-1-piperidinyl)-1,7-dihydro-1-methyl-7-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 666702-70-1 CAPLUS

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-1-methyl-7-(3-methyl-2-butenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 666702-73-4 CAPLUS

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-1,2-dimethyl-7-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 666702-77-8 CAPLUS

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-1-methyl-7-(3-methyl-2-butenyl)-2-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 666702-82-5 CAPLUS

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-1-methyl-7-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 666702-86-9 CAPLUS

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-2-(methylthio)-7-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 666702-89-2 CAPLUS

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-7-(phenylmethyl)-2-[(phenylmethyl)thio]- (9CI) (CA INDEX NAME)




RN 666702-91-6 CAPLUS

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-1-methyl-2-(methylthio)-7-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 666702-94-9 CAPLUS

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-2-(methylthio)-1-(2-oxo-2-phenylethyl)-7-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 666702-97-2 CAPLUS

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-2-(methylthio)-1,7-bis(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 666703-02-2 CAPLUS

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-2-(methylthio)-1-(2-phenylethyl)-7-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 666703-05-5 CAPLUS

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-1-(2-oxo-2-phenylethyl)-7-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 666703-09-9 CAPLUS

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-2-[[[4-fluorophenyl)methyl]amino]-1,7-dihydro-1-methyl-7-(phenylmethyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 666702-31-4


CMF C25 H28 F N7 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 666703-11-3 CAPLUS


CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-1-methyl-2-[(2-

phenylethyl)amino]-7-(phenylmethyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 666702-35-8


CMF C26 H31 N7 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 666703-14-6 CAPLUS

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-1-methyl-2-[(1-methylethyl)amino]-7-(phenylmethyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 666702-40-5


CMF C21 H29 N7 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 666703-17-9 CAPLUS
CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-1-methyl-2-(methylamino)-7-(phenylmethyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 666702-45-0


CMF C19 H25 N7 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 666703-20-4 CAPLUS
CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-2-(cyclohexylamino)-1,7-dihydro-1-methyl-7-(phenylmethyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 666702-50-7


CMF C24 H33 N7 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 666703-21-5 CAPLUS

CN 6H-Purin-6-one, 8-(3-amino-1-piperidiny1)-2-[(cyclohexylmethyl)amino]-1,7-dihydro-1-methyl-7-(phenylmethyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 666702-56-3


CMF C25 H35 N7 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 666703-25-9 CAPLUS

CN 6H-Purin-6-one, 8-(3-amino-1-piperidiny1)-2-(dimethylamino)-1,7-dihydro-1-methyl-7-(phenylmethyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 666702-63-2


CMF C20 H27 N7 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 666703-27-1 CAPLUS

CN 6H-Purin-6-one, 2-amino-8-(3-amino-1-piperidinyl)-1,7-dihydro-1-methyl-7-(phenylmethyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 666702-67-6


CMF C18 H23 N7 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 666703-29-3 CAPLUS


CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-1-methyl-7-(3-methyl-2-butenyl)-2-[(phenylmethyl)amino]-, trifluoroacetate (9CI) (CA INDEX NAME)

NAME)

CM 1

CRN 666702-70-1


CMF C23 H31 N7 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 666703-31-7 CAPLUS

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-1,2-dimethyl-7-(phenylmethyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 666702-73-4


CMF C19 H24 N6 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 666703-33-9 CAPLUS

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-1-methyl-7-(3-methyl-2-butenyl)-2-(2-phenylethyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 666702-77-8


CMF C24 H32 N6 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 666703-35-1 CAPLUS


CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-1-methyl-7-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 666703-37-3 CAPLUS


CN 6H-Purin-6-one, 8-(3-amino-1-piperidiny1)-1,7-dihydro-2-(methylthio)-7-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 666703-41-9 CAPLUS


CN 6H-Purin-6-one, 8-(3-amino-1-piperidiny1)-1,7-dihydro-2-(methylthio)-1-(2-oxo-2-phenylethyl)-7-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 666703-45-3 CAPLUS


CN 6H-Purin-6-one, 8-(3-amino-1-piperidiny1)-1,7-dihydro-2-(methylthio)-1,7-bis(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 666703-47-5 CAPLUS


CN 6H-Purin-6-one, 8-(3-amino-1-piperidiny1)-1,7-dihydro-2-(methylthio)-1-(2-phenylethyl)-7-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 666703-50-0 CAPLUS


CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-1-methyl-7-(phenylmethyl)-2-[(phenylmethyl)thio]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 666703-52-2 CAPLUS

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-1-methyl-2-[(2-phenylethyl)thio]-7-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 666703-54-4 CAPLUS

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-1-(2-oxo-2-phenylethyl)-7-(phenylmethyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 666703-05-5


CMF C25 H26 N6 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 666703-56-6 CAPLUS

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-7-(phenylmethyl)-2-[(phenylmethyl)thio]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 666702-89-2


CMF C24 H26 N6 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 666704-19-4 CAPLUS


CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-1-methyl-7-(phenylmethyl)-2-[(phenylmethyl)amino]-, trifluoroacetate (9CI) (CA INDEX NAME)

NAME)

CM 1

CRN 666702-26-7


CMF C25 H29 N7 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 666704-74-1 CAPLUS

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-1-methyl-2-(methylthio)-7-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

IT 666703-62-4P 666703-64-6P 666703-66-8P
 666703-68-0P 666703-74-8P 666703-76-0P
 666703-78-2P 666703-80-6P 666703-82-8P
 666703-84-0P 666703-86-2P 666703-88-4P
 666703-90-8P 666703-92-0P 666703-94-2P
 666703-96-4P 666703-98-6P 666704-00-3P
 666704-02-5P 666704-04-7P 666704-06-9P
 666704-08-1P 666704-09-2P 666704-11-6P
 666704-12-7P 666704-13-8P 666704-14-9P
 666704-15-0P 666704-16-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)

(preparation of purine derivs. as dipeptidylpeptidase IV inhibitors)


RN 666703-62-4 CAPLUS

CN Carbamic acid, [1-[6,7-dihydro-6-oxo-7-(phenylmethyl)-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 666703-64-6 CAPLUS

CN Carbamic acid, [1-[6,7-dihydro-1-methyl-6-oxo-7-(phenylmethyl)-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 666703-66-8 CAPLUS

CN Carbamic acid, [1-[6,7-dihydro-6-oxo-1-(2-oxo-2-phenylethyl)-7-(phenylmethyl)-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 666703-68-0 CAPLUS

CN Carbamic acid, [1-[6,7-dihydro-2-(methylthio)-6-oxo-7-(phenylmethyl)-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 666703-74-8 CAPLUS

CN Carbamic acid, [1-[6,7-dihydro-6-oxo-7-(phenylmethyl)-2-[(phenylmethyl)thio]-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 666703-76-0 CAPLUS

CN Carbamic acid, [1-[6,7-dihydro-2-(methylthio)-6-oxo-7-(2-propenyl)-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 666703-78-2 CAPLUS

CN Carbamic acid, [1-[6,7-dihydro-6-oxo-2-[(2-phenylethyl)thio]-7-(phenylmethyl)-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 666703-80-6 CAPLUS

CN Carbamic acid, [1-[6,7-dihydro-1-methyl-2-(methylthio)-6-oxo-7-(phenylmethyl)-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 666703-82-8 CAPLUS

CN Carbamic acid, [1-[6,7-dihydro-2-(methylthio)-6-oxo-1-(2-oxo-2-phenylethyl)-7-(phenylmethyl)-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 666703-84-0 CAPLUS

CN Carbamic acid, [1-[6,7-dihydro-1-methyl-7-(3-methyl-2-butenyl)-2-(methylthio)-6-oxo-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 666703-86-2 CAPLUS

CN Carbamic acid, [1-[6,7-dihydro-2-(methylthio)-6-oxo-1,7-bis(phenylmethyl)-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 666703-88-4 CAPLUS

CN Carbamic acid, [1-[6,7-dihydro-1-methyl-6-oxo-7-(phenylmethyl)-2-[(phenylmethyl)thio]-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 666703-90-8 CAPLUS

CN Carbamic acid, [1-[6,7-dihydro-1-methyl-6-oxo-2-[(2-phenylethyl)thio]-7-(phenylmethyl)-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 666703-92-0 CAPLUS

CN Carbamic acid, [1-[6,7-dihydro-1-methyl-2-(methylsulfinyl)-6-oxo-7-(phenylmethyl)-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 666703-94-2 CAPLUS

CN Carbamic acid, [1-[6,7-dihydro-1-methyl-2-(methylsulfonyl)-6-oxo-7-(phenylmethyl)-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 666703-96-4 CAPLUS

CN Carbamic acid, [1-[6,7-dihydro-1-methyl-7-(3-methyl-2-butenyl)-2-(methylsulfinyl)-6-oxo-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 666703-98-6 CAPLUS

CN Carbamic acid, [1-[6,7-dihydro-1-methyl-6-oxo-7-(phenylmethyl)-2-[(phenylmethyl)amino]-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 666704-00-3 CAPLUS

CN Carbamic acid, [1-[2-[[4-fluorophenyl)methyl]amino]-6,7-dihydro-1-methyl-6-oxo-7-(phenylmethyl)-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 666704-02-5 CAPLUS


CN Carbamic acid, [1-[6,7-dihydro-1-methyl-6-oxo-2-[(2-phenylethyl)amino]-7-(phenylmethyl)-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 666704-04-7 CAPLUS


CN Carbamic acid, [1-[6,7-dihydro-1-methyl-2-[(1-methylethyl)amino]-6-oxo-7-(phenylmethyl)-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester

(9CI) (CA INDEX NAME)




RN 666704-06-9 CAPLUS

CN Carbamic acid, [1-[6,7-dihydro-1-methyl-2-(methylamino)-6-oxo-7-(phenylmethyl)-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester
(9CI) (CA INDEX NAME)




RN 666704-08-1 CAPLUS

CN Carbamic acid, [1-[2-(cyclohexylamino)-6,7-dihydro-1-methyl-6-oxo-7-(phenylmethyl)-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester
(9CI) (CA INDEX NAME)



RN 666704-09-2 CAPLUS


CN Carbamic acid, [1-[2-[(cyclohexylmethyl)amino]-6,7-dihydro-1-methyl-6-oxo-7-(phenylmethyl)-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester
(9CI) (CA INDEX NAME)



RN 666704-11-6 CAPLUS


CN Carbamic acid, [1-[2-(dimethylamino)-6,7-dihydro-1-methyl-6-oxo-7-(phenylmethyl)-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester

(9CI) (CA INDEX NAME)




RN 666704-12-7 CAPLUS

CN Carbamic acid, [1-[2-amino-6,7-dihydro-1-methyl-6-oxo-7-(phenylmethyl)-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 666704-13-8 CAPLUS

CN Carbamic acid, [1-[6,7-dihydro-1-methyl-7-(3-methyl-2-butenyl)-6-oxo-2-[(phenylmethyl)amino]-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 666704-14-9 CAPLUS


CN Carbamic acid, [1-[6,7-dihydro-1,2-dimethyl-6-oxo-7-(phenylmethyl)-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 666704-15-0 CAPLUS


CN Carbamic acid, [1-[6,7-dihydro-1-methyl-7-(3-methyl-2-butenyl)-6-oxo-2-(2-phenylethyl)-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI)

(CA INDEX NAME)



RN 666704-16-1 CAPLUS

CN Carbamic acid, [1-[6,7-dihydro-2-(methylthio)-6-oxo-1-(2-phenylethyl)-7-(phenylmethyl)-1H-purin-8-yl]-3-piperidinyll-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L32 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1992:651141 CAPLUS

DOCUMENT NUMBER: 117:251141

TITLE: Preparation of imidazo[2,1-b]purin-4(5H)-ones and analogs as phosphodiesterase inhibitors
INVENTOR(S): Neustadt, Bernard R.; Lindo, Neil A.; McKittrick, Brian A.

PATENT ASSIGNEE(S): Schering Corp., USA

SOURCE: PCT Int. Appl., 89 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9119717	A1	19911226	WO 1991-US4154	19910620
W: AU, BB, BG, BR, CA, CS, FI, HU, JP, KP, KR, LK, MC, MG, MW, NO, PL, RO, SD, SU, US				
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN, GR, IT, LU, ML, MR, NL, SE, SN, TD, TG				
ZA 9104727	A	19920325	ZA 1991-4727	19910619
CA 2085733	AA	19911222	CA 1991-2085733	19910620
CA 2085733	C	19960305		
AU 9181992	A1	19920107	AU 1991-81992	19910620
AU 651607	B2	19940728		
EP 538332	A1	19930428	EP 1991-912779	19910620
EP 538332	B1	19970723		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 05508647	T2	19931202	JP 1991-512084	19910620
JP 07047589	B4	19950524		

HU 65623	A2	19940728	HU 1992-4032	19910620
PL 169481	B1	19960731	PL 1991-297299	19910620
CZ 281920	B6	19970416	CZ 1992-3749	19910620
RU 2080322	C1	19970527	RU 1992-16466	19910620
AT 155786	E	19970815	AT 1991-912779	19910620
US 5393755	A	19950228	US 1992-949811	19921214
NO 9204940	A	19921218	NO 1992-4940	19921218
PRIORITY APPLN. INFO.:			US 1990-541568	A2 19900621
OTHER SOURCE(S):	MARPAT 117:251141		WO 1991-US4154	A 19910620
ED Entered STN:	26 Dec 1992			
GI				



I



II

AB Title compds. [I; R1 = H, (ar)alkyl, hydroxyalkyl; R2 = H, (cyclo)alkyl, (hetero)aryl, aralkyl, etc.; R3 = H, halo, CF3, alkoxy, (cyclo)alkyl, etc.; R4 - R7 = H, (cyclo)alkyl, aryl; R4R5, R6R7, R5R6 = atoms to complete a ring; X = O, S; n = 0, 1] were prepared. Thus, 2-chloro-1-methyl-7-benzylpurin-6-one (preparation given) was condensed with 1-hydroxy-7-aminobicyclo[3.3.0]octane (preparation given) and the product cyclized to give, after optical resolution and deprotection, title compound (+)-II which gave 45 mm Hg reduction in mean blood pressure in rats at 5 mg/kg orally.

IT 140396-39-0P 140396-40-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of, in preparation of phosphodiesterase inhibitors)

RN 140396-39-0 CAPLUS

CN 6H-Purin-6-one, 1,7-dihydro-2-[(2-hydroxycyclopentyl)amino]-1-methyl-8-phenyl-7-(phenylmethyl)-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 140396-40-3 CAPLUS

CN 6H-Purin-6-one, 1,7-dihydro-2-[(2-hydroxycyclohexyl)amino]-1-methyl-8-phenyl-7-(phenylmethyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L32 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1989:114567 CAPLUS

DOCUMENT NUMBER: 110:114567

TITLE: Preparation of (4-Piperidinylmethyl and -hetero)purines as antiallergic agents

INVENTOR(S): Janssens, Frans Eduard; Diels, Gaston Stanislas Marcella

PATENT ASSIGNEE(S): Janssen Pharmaceutica N. V., Belg.

SOURCE: Eur. Pat. Appl., 102 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 206415	A2	19861230	EP 1986-201048	19860617
EP 206415	A3	19880316		
EP 206415	B1	19930127		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
CA 1267889	A1	19900417	CA 1986-511113	19860609
SU 1581221	A3	19900723	SU 1986-4027617	19860610
AT 85055	E	19930215	AT 1986-201048	19860617
JP 62000487	A2	19870106	JP 1986-143155	19860620
ES 556381	A1	19871116	ES 1986-556381	19860620
DK 8602952	A	19861225	DK 1986-2952	19860623
DK 169073	B1	19940808		
FI 8602655	A	19861225	FI 1986-2655	19860623
FI 85704	B	19920214		
FI 85704	C	19920525		
NO 8602504	A	19861229	NO 1986-2504	19860623
NO 163956	B	19900507		
NO 163956	C	19900815		
AU 8659191	A1	19870108	AU 1986-59191	19860623
AU 588890	B2	19890928		
HU 42095	A2	19870629	HU 1986-2631	19860623
HU 199143	B	19900129		
ZA 8604677	A	19880224	ZA 1986-4677	19860623
IL 79193	A1	19901105	IL 1986-79193	19860623
US 5041448	A	19910820	US 1989-323250	19890309
US 5258380	A	19931102	US 1991-719273	19910621
PRIORITY APPLN. INFO.:			GB 1985-15934	A 19850624

US 1986-858339

B1 19860501


EP 1986-201048

A 19860617

US 1989-323250

A3 19890309

ED Entered STN: 03 Apr 1989
GI




AB The title compds. I [A1:A2:A3:A4 = N:CHN:CH, CH:NCH:N, wherein 1 or 2 H may each be replaced by halo, C1-6 alkyl, C1-6 alkoxy, F3C, HO; R1 = H, C1-10 alkyl, C3-6 cycloalkyl, etc.; R2 = H, C1-6 alkyl; B = H2C, O, S, SO, SO2, NR, R = H, C1-6 alkyl, C3-6 cycloalkyl, etc.; L = (un)substituted methoxyalkyl, -methylthioalkyl, -alkoxycarbonyl, alkylthio, (un)substituted alkyl, optionally with heteroatom interrupters, (un)substituted N-heterocyclyl, (un)substituted pyrimidinylalkoxyalkyl, -thioalkyl, etc., with restrictions] and their salts, useful as antiallergic agents, were prepared 2-Ethenylpyridine, 9-[(4-fluorophenyl)methyl]-N-(4-piperidinyl)-9H-purin-8-amine and BuOH were refluxed overnight to give 9-[(4-fluorophenyl)methyl]-N-[1-[2-(2-pyridinyl)ethyl]-4-piperidinyl]-9H-purin-8-amine (II). In tests in rats against compound 48/80, a potent histamine releasing agent, at 0.5 mg/kg, the ED50 of II was 0.01 mg/kg.

IT 116062-65-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and alkylation of)

RN 116062-65-8 CAPLUS

CN 6H-Purin-6-one, 7-[(4-fluorophenyl)methyl]-1,7-dihydro-8-(4-piperidinylamino)-, dihydrobromide (9CI) (CA INDEX NAME)



●2 HBr

IT 116062-74-9P 116062-92-1P 116063-06-0P


116063-46-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as antiallergic agent)

RN 116062-74-9 CAPLUS


CN 6H-Purin-6-one, 8-[[1-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-4-piperidinyl]amino]-7-[(4-fluorophenyl)methyl]-1,7-dihydro- (9CI) (CA

INDEX NAME)




RN 116062-92-1 CAPLUS

CN 6H-Purin-6-one, 7-[(4-fluorophenyl)methyl]-1,7-dihydro-8-[[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl]amino]- (9CI) (CA INDEX NAME)




RN 116063-06-0 CAPLUS

CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-[[7-[(4-fluorophenyl)methyl]-6,7-dihydro-6-oxo-1H-purin-8-yl]amino]-1-piperidinyl]ethyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 116063-46-8 CAPLUS


CN 6H-Purin-6-one, 7-[(4-fluorophenyl)methyl]-1,7-dihydro-8-[(1-methyl-4-piperidinyl)amino]- (9CI) (CA INDEX NAME)




L32 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1975:85532 CAPLUS
DOCUMENT NUMBER: 82:85532
TITLE: Nuclear magnetic resonance study of hindered rotation
in 8-phenylpurines
AUTHOR(S): Bergmann, F.; Tamir, I.; Neiman, Z.; Lichtenberg, D.
CORPORATE SOURCE: Hadassah Med. Sch., Hebrew Univ., Jerusalem, Israel
SOURCE: Tetrahedron (1974), 30(17), 3045-51
CODEN: TETRAB; ISSN: 0040-4020
DOCUMENT TYPE: Journal
LANGUAGE: English
ED Entered STN: 12 May 1984
AB In the PMR spectrum of 8-phenylpurines, the multiplet of the ortho protons
appeared downfield of the multiplet characteristic for meta and para
protons. The separation of the centers of these 2 signals diminished with
increasing steric interference between the Ph ring and substituents in the
imidazole moiety. The contribution of the purine ring current to the
chemical shifts of the aromatic protons was calculated by the theory of C. E.
Johnson and F. A. Bovey (1958) and the torsion angles between the Ph ring
and the plane of the purine system were derived.
IT 32533-56-5 32533-63-4 32533-68-9
RL: PRP (Properties)
(hindered rotation in, PMR in relation to)
RN 32533-56-5 CAPLUS
CN 6H-Purin-6-one, 1,7-dihydro-1,7-dimethyl-8-phenyl- (9CI) (CA INDEX NAME)




RN 32533-63-4 CAPLUS
CN 6H-Purine-6-thione, 1,7-dihydro-1,7-dimethyl-8-phenyl- (9CI) (CA INDEX
NAME)




RN 32533-68-9 CAPLUS
CN 6H-Purine-6-thione, 1,7-dihydro-7-methyl-8-phenyl- (9CI) (CA INDEX NAME)




L32 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1971:435951 CAPLUS
DOCUMENT NUMBER: 75:35951
TITLE: Methylation of 6-(methylthio)-8-phenylpurines
AUTHOR(S): Bergmann, F.; Neiman, Z.; Lichtenberg, D.; Deutsch, J.
CORPORATE SOURCE: Hadassah Med. Sch., Heb. Univ., Jerusalem, Israel
SOURCE: Journal of the Chemical Society [Section] C: Organic
(1971), (10), 1822-9
CODEN: JSOOAX; ISSN: 0022-4952
DOCUMENT TYPE: Journal
LANGUAGE: English
ED Entered STN: 12 May 1984
AB Methylation of 6-(methylthio)-8-phenylpurine (I) derivs. with MeI-DMF
always gave a single product. I and its 7- and 9-Me derivs. were
substituted at N-3; the 1-Me derivative was attacked at N-9 and the 3-Me
derivative at N-7. The most important difference between the 8-unsubstituted
and 8-Ph series was found for the 9-Me derivative. Similarly,
9-methyl-8-phenylhypoxanthine was converted into the corresponding
3,9-dimethyl derivative, in contrast to the behavior of the nonphenylated
compound
IT 32533-56-5P 32533-63-4P 32533-68-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 32533-56-5 CAPLUS
CN 6H-Purin-6-one, 1,7-dihydro-1,7-dimethyl-8-phenyl- (9CI) (CA INDEX NAME)



RN 32533-63-4 CAPLUS
CN 6H-Purine-6-thione, 1,7-dihydro-1,7-dimethyl-8-phenyl- (9CI) (CA INDEX NAME)



RN 32533-68-9 CAPLUS
 CN 6H-Purine-6-thione, 1,7-dihydro-7-methyl-8-phenyl- (9CI) (CA INDEX NAME)



L32 ANSWER 13 OF 17 USPATFULL on STN
 ACCESSION NUMBER: 2004:159424 USPATFULL
 TITLE: New purine derivatives, the preparation thereof and their use as pharmaceutical compositions
 INVENTOR(S): Maier, Roland, Biberach, GERMANY, FEDERAL REPUBLIC OF
 Himmelsbach, Frank, Mittelbiberach, GERMANY, FEDERAL REPUBLIC OF
 Eckhardt, Matthias, Biberach, GERMANY, FEDERAL REPUBLIC OF
 Langkopf, Elke, Warthausen, GERMANY, FEDERAL REPUBLIC OF
 Mark, Michael, Biberach, GERMANY, FEDERAL REPUBLIC OF
 Lotz, Ralf R. H., Schemmerhofen, GERMANY, FEDERAL REPUBLIC OF
 PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

This work

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004122228	A1	20040624
APPLICATION INFO.:	US 2003-634047	A1	20030804 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2002-10238477	20020822
	US 2002-408021P	20020904 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877	
NUMBER OF CLAIMS:	8	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3088	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	The invention relates to new purine derivatives of general formula ##STR1##	

wherein R.sup.1 to R.sup.4 are defined as in the claims, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV), the preparation thereof, the use thereof for the prevention or treatment of diseases or conditions associated with an increased DPP-IV activity or capable of being prevented or alleviated by reducing the DPP-IV activity, particularly type I or type II diabetes mellitus, the pharmaceutical compositions containing a compound of general formula (I) or a physiologically acceptable salt thereof as well as processes for the preparation thereof.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 666702-26-7P 666702-31-4P 666702-35-8P
 666702-40-5P 666702-45-0P 666702-50-7P
 666702-56-3P 666702-63-2P 666702-67-6P
 666702-70-1P 666702-73-4P 666702-77-8P
 666702-82-5P 666702-86-9P 666702-89-2P
 666702-91-6P 666702-94-9P 666702-97-2P
 666703-02-2P 666703-05-5P 666703-09-9P
 666703-11-3P 666703-14-6P 666703-17-9P
 666703-20-4P 666703-21-5P 666703-25-9P
 666703-27-1P 666703-29-3P 666703-31-7P
 666703-33-9P 666703-35-1P 666703-37-3P
 666703-41-9P 666703-45-3P 666703-47-5P
 666703-50-0P 666703-52-2P 666703-54-4P
 666703-56-6P 666704-19-4P 666704-74-1P

(preparation of purine derivs. as dipeptidylpeptidase IV inhibitors)


RN 666702-26-7 USPATFULL

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-1-methyl-7-(phenylmethyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 666702-31-4 USPATFULL

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-2-[[4-fluorophenyl)methyl]amino]-1,7-dihydro-1-methyl-7-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 666702-35-8 USPATFULL

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-1-methyl-2-[(2-phenylethyl)amino]-7-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 666702-40-5 USPATFULL

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-1-methyl-2-[(1-methylethyl)amino]-7-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 666702-45-0 USPATFULL

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-1-methyl-2-(methylethylamino)-7-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 666702-50-7 USPATFULL

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-2-(cyclohexylamino)-1,7-dihydro-1-methyl-7-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 666702-56-3 USPATFULL

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-2-[(cyclohexylmethyl)amino]-1,7-dihydro-1-methyl-7-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 666702-63-2 USPATFULL

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-2-(dimethylamino)-1,7-dihydro-1-methyl-7-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 666702-67-6 USPATFULL

CN 6H-Purin-6-one, 2-amino-8-(3-amino-1-piperidinyl)-1,7-dihydro-1-methyl-7-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 666702-70-1 USPATFULL

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-1-methyl-7-(3-methyl-2-butenyl)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 666702-73-4 USPATFULL

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-1,2-dimethyl-7-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 666702-77-8 USPATFULL

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-1-methyl-7-(3-methyl-2-butenyl)-2-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 666702-82-5 USPATFULL

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-1-methyl-7-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 666702-86-9 USPATFULL

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-2-(methylthio)-7-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 666702-89-2 USPATFULL

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-7-(phenylmethyl)-2-[(phenylmethyl)thio]- (9CI) (CA INDEX NAME)




RN 666702-91-6 USPATFULL

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-1-methyl-2-(methylthio)-7-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 666702-94-9 USPATFULL

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-2-(methylthio)-1-(2-oxo-2-phenylethyl)-7-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 666702-97-2 USPATFULL

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-2-(methylthio)-1,7-bis(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 666703-02-2 USPATFULL

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-2-(methylthio)-1-(2-phenylethyl)-7-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 666703-05-5 USPATFULL

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-1-(2-oxo-2-phenylethyl)-7-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 666703-09-9 USPATFULL

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-2-[[4-(4-fluorophenyl)methyl]amino]-1,7-dihydro-1-methyl-7-(phenylmethyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 666702-31-4


CMF C25 H28 F N7 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 666703-11-3 USPATFULL


CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-1-methyl-2-[(2-

phenylethyl) amino]-7-(phenylmethyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 666702-35-8


CMF C26 H31 N7 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 666703-14-6 USPATFULL

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-1-methyl-2-[(1-methylethyl) amino]-7-(phenylmethyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 666702-40-5


CMF C21 H29 N7 O



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 666703-17-9 USPATFULL
 CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-1-methyl-2-(methylamino)-7-(phenylmethyl)-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 666702-45-0
 CMF C19 H25 N7 O



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 666703-20-4 USPATFULL
 CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-2-(cyclohexylamino)-1,7-dihydro-1-methyl-7-(phenylmethyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 666702-50-7
 CMF C24 H33 N7 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 666703-21-5 USPATFULL

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-2-[(cyclohexylmethyl)amino]-1,7-dihydro-1-methyl-7-(phenylmethyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 666702-56-3


CMF C25 H35 N7 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 666703-25-9 USPATFULL

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-2-(dimethylamino)-1,7-dihydro-1-methyl-7-(phenylmethyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 666702-63-2


CMF C20 H27 N7 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 666703-27-1 USPATFULL

CN 6H-Purin-6-one, 2-amino-8-(3-amino-1-piperidinyl)-1,7-dihydro-1-methyl-7-(phenylmethyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 666702-67-6


CMF C18 H23 N7 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 666703-29-3 USPATFULL


CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-1-methyl-7-(3-methyl-2-butenyl)-2-[(phenylmethyl)amino]-, trifluoroacetate (9CI) (CA INDEX NAME)

NAME)

CM 1

CRN 666702-70-1


CMF C23 H31 N7 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 666703-31-7 USPATFULL

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-1,2-dimethyl-7-(phenylmethyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 666702-73-4


CMF C19 H24 N6 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 666703-33-9 USPATFULL

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-1-methyl-7-(3-methyl-2-butenyl)-2-(2-phenylethyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 666702-77-8


CMF C24 H32 N6 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 666703-35-1 USPATFULL


CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-1-methyl-7-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 666703-37-3 USPATFULL


CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-2-(methylthio)-7-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 666703-41-9 USPATFULL


CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-2-(methylthio)-1-(2-oxo-2-phenylethyl)-7-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 666703-45-3 USPATFULL


CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-2-(methylthio)-1,7-bis(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 666703-47-5 USPATFULL


CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-2-(methylthio)-1-(2-phenylethyl)-7-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 666703-50-0 USPATFULL


CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-1-methyl-7-(phenylmethyl)-2-[(phenylmethyl)thio]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 666703-52-2 USPATFULL

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-1-methyl-2-[(2-phenylethyl)thio]-7-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 666703-54-4 USPATFULL

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-1-(2-oxo-2-phenylethyl)-7-(phenylmethyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 666703-05-5


CMF C25 H26 N6 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 666703-56-6 USPATFULL

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-7-(phenylmethyl)-2-[(phenylmethyl)thio]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 666702-89-2


CMF C24 H26 N6 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 666704-19-4 USPATFULL


CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-1-methyl-7-

(phenylmethyl)-2-[(phenylmethyl)amino]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 666702-26-7


CMF C25 H29 N7 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 666704-74-1 USPATFULL

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-1,7-dihydro-1-methyl-2-(methylthio)-7-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

IT 666703-62-4P 666703-64-6P 666703-66-8P
 666703-68-0P 666703-74-8P 666703-76-0P
 666703-78-2P 666703-80-6P 666703-82-8P
 666703-84-0P 666703-86-2P 666703-88-4P
 666703-90-8P 666703-92-0P 666703-94-2P
 666703-96-4P 666703-98-6P 666704-00-3P
 666704-02-5P 666704-04-7P 666704-06-9P
 666704-08-1P 666704-09-2P 666704-11-6P
 666704-12-7P 666704-13-8P 666704-14-9P
 666704-15-0P 666704-16-1P

(preparation of purine derivs. as dipeptidylpeptidase IV inhibitors)


RN 666703-62-4 USPATFULL

CN Carbamic acid, [1-[6,7-dihydro-6-oxo-7-(phenylmethyl)-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 666703-64-6 USPATFULL

CN Carbamic acid, [1-[6,7-dihydro-1-methyl-6-oxo-7-(phenylmethyl)-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 666703-66-8 USPATFULL

CN Carbamic acid, [1-[6,7-dihydro-6-oxo-1-(2-oxo-2-phenylethyl)-7-(phenylmethyl)-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 666703-68-0 USPATFULL

CN Carbamic acid, [1-[6,7-dihydro-2-(methylthio)-6-oxo-7-(phenylmethyl)-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 666703-74-8 USPATFULL

CN Carbamic acid, [1-[6,7-dihydro-6-oxo-7-(phenylmethyl)-2-[(phenylmethyl)thio]-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 666703-76-0 USPATFULL

CN Carbamic acid, [1-[6,7-dihydro-2-(methylthio)-6-oxo-7-(2-propenyl)-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 666703-78-2 USPATFULL

CN Carbamic acid, [1-[6,7-dihydro-6-oxo-2-[(2-phenylethyl)thio]-7-(phenylmethyl)-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 666703-80-6 USPATFULL

CN Carbamic acid, [1-[6,7-dihydro-1-methyl-2-(methylthio)-6-oxo-7-(phenylmethyl)-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 666703-82-8 USPATFULL

CN Carbamic acid, [1-[6,7-dihydro-2-(methylthio)-6-oxo-1-(2-oxo-2-phenylethyl)-7-(phenylmethyl)-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 666703-84-0 USPATFULL

CN Carbamic acid, [1-[6,7-dihydro-1-methyl-7-(3-methyl-2-butenyl)-2-(methylthio)-6-oxo-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 666703-86-2 USPATFULL

CN Carbamic acid, [1-[6,7-dihydro-2-(methylthio)-6-oxo-1,7-bis(phenylmethyl)-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 666703-88-4 USPATFULL

CN Carbamic acid, [1-[6,7-dihydro-1-methyl-6-oxo-7-(phenylmethyl)-2-[(phenylmethyl)thio]-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 666703-90-8 USPATFULL

CN Carbamic acid, [1-[6,7-dihydro-1-methyl-6-oxo-2-[(2-phenylethyl)thio]-7-(phenylmethyl)-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 666703-92-0 USPATFULL

CN Carbamic acid, [1-[6,7-dihydro-1-methyl-2-(methylsulfinyl)-6-oxo-7-(phenylmethyl)-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 666703-94-2 USPATFULL

CN Carbamic acid, [1-[6,7-dihydro-1-methyl-2-(methylsulfonyl)-6-oxo-7-(phenylmethyl)-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 666703-96-4 USPATFULL

CN Carbamic acid, [1-[6,7-dihydro-1-methyl-7-(3-methyl-2-butenyl)-2-(methylsulfinyl)-6-oxo-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 666703-98-6 USPATFULL

CN Carbamic acid, [1-[6,7-dihydro-1-methyl-6-oxo-7-(phenylmethyl)-2-[(phenylmethyl)amino]-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 666704-00-3 USPATFULL

CN Carbamic acid, [1-[2-[(4-fluorophenyl)methyl]amino]-6,7-dihydro-1-methyl-6-oxo-7-(phenylmethyl)-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 666704-02-5 USPATFULL


CN Carbamic acid, [1-[6,7-dihydro-1-methyl-6-oxo-2-[(2-phenylethyl)amino]-7-(phenylmethyl)-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 666704-04-7 USPATFULL


CN Carbamic acid, [1-[6,7-dihydro-1-methyl-2-[(1-methylethyl)amino]-6-oxo-7-(phenylmethyl)-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester

(9CI) (CA INDEX NAME)




RN 666704-06-9 USPATFULL

CN Carbamic acid, [1-[6,7-dihydro-1-methyl-2-(methyamino)-6-oxo-7-(phenylmethyl)-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester
(9CI) (CA INDEX NAME)




RN 666704-08-1 USPATFULL

CN Carbamic acid, [1-[2-(cyclohexylamino)-6,7-dihydro-1-methyl-6-oxo-7-(phenylmethyl)-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester
(9CI) (CA INDEX NAME)



RN 666704-09-2 USPATFULL


CN Carbamic acid, [1-[2-[(cyclohexylmethyl)amino]-6,7-dihydro-1-methyl-6-oxo-7-(phenylmethyl)-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester
(9CI) (CA INDEX NAME)



RN 666704-11-6 USPATFULL


CN Carbamic acid, [1-[2-(dimethylamino)-6,7-dihydro-1-methyl-6-oxo-7-(phenylmethyl)-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester

(9CI) (CA INDEX NAME)




RN 666704-12-7 USPATFULL

CN Carbamic acid, [1-[2-amino-6,7-dihydro-1-methyl-6-oxo-7-(phenylmethyl)-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 666704-13-8 USPATFULL

CN Carbamic acid, [1-[6,7-dihydro-1-methyl-7-(3-methyl-2-butenyl)-6-oxo-2-[(phenylmethyl)amino]-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 666704-14-9 USPATFULL


CN Carbamic acid, [1-[6,7-dihydro-1,2-dimethyl-6-oxo-7-(phenylmethyl)-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 666704-15-0 USPATFULL


CN Carbamic acid, [1-[6,7-dihydro-1-methyl-7-(3-methyl-2-butenyl)-6-oxo-2-(2-phenylethyl)-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester

(9CI) (CA INDEX NAME)



RN 666704-16-1 USPATFULL

CN Carbamic acid, [1-[6,7-dihydro-2-(methylthio)-6-oxo-1-(2-phenylethyl)-7-(phenylmethyl)-1H-purin-8-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester
(9CI) (CA INDEX NAME)



L32 ANSWER 14 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2004:152106 USPATFULL

TITLE: Condensed imidazole derivatives

INVENTOR(S): Yoshikawa, Seiji, Kashima-gun, JAPAN
Emori, Eita, Tsuchiura-shi, JAPAN
Matsuura, Fumiyoshi, Tsukuba-shi, JAPAN
Clark, Richard, Tsuchiura-shi, JAPAN
Ikuta, Hironori, Ushiku-shi, JAPAN
Kira, Kazunobu, Tsukuba-shi, JAPAN
Yasuda, Nobuyuki, Tsuchiura-shi, JAPAN
Nagakura, Tadashi, Ushiku-shi, JAPAN
Yamazaki, Kazuto, Tsukuba-shi, JAPAN

PATENT ASSIGNEE(S): Eisai Co., Ltd., Tokyo, JAPAN (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004116328	A1	20040617
APPLICATION INFO.:	US 2003-257002	A1	20030606 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 2002-166069	20020606
	JP 2002-209373	20020718
	JP 2002-307750	20021023

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO
CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834

NUMBER OF CLAIMS: 33

EXEMPLARY CLAIM: 1

LINE COUNT: 9667

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is related to compounds represented by the following formula, or salts or hydrates thereof ##STR1##

wherein,

T.sup.1 represents a 4- to 12-membered heterocyclic group containing one or two nitrogen atoms in the ring, which is a monocyclic or bicyclic structure that may have one or more substituents;

X represents a C.sub.1-6 alkyl group which may have one or more substituents, or such;

Z.sup.1 and Z.sup.2 each independently represent a nitrogen atom or a group represented by the formula --CR.sup.2--;

R.sup.1 and R.sup.2 independently represent a hydrogen atom, a C.sub.1-6 alkyl group which may have one or more substituents, or a C.sub.1-6 alkoxy group which may have one or more substituents, or such.

These are novel compounds that exhibit an excellent DPPIV-inhibiting activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 635715-41-2P 635715-43-4P 635715-48-9P
635715-52-5P 635715-57-0P 635715-58-1P
635715-60-5P 635715-62-7P 635715-63-8P
635715-64-9P 635715-66-1P 635715-68-3P
635715-79-6P 635715-81-0P 635715-83-2P
635715-85-4P 635715-87-6P 635715-91-2P
635715-93-4P 635715-95-6P 635715-97-8P
635715-99-0P 635716-01-7P 635716-05-1P
635716-09-5P 635716-11-9P 635716-13-1P
635716-15-3P 635716-17-5P 635716-19-7P
635716-23-3P 635716-27-7P 635716-29-9P
635716-31-3P 635716-33-5P 635716-35-7P
635716-39-1P 635716-45-9P 635716-47-1P
635716-53-9P 635716-55-1P 635716-57-3P
635716-59-5P 635716-65-3P 635716-67-5P
635716-69-7P 635716-71-1P 635716-73-3P
635716-75-5P 635716-77-7P 635716-79-9P
635716-81-3P 635716-86-8P 635716-90-4P
635716-93-7P 635717-00-9P 635717-02-1P
635717-05-4P 635717-08-7P 635717-10-1P
635717-13-4P 635717-16-7P 635717-18-9P
635717-20-3P 635717-22-5P 635717-24-7P
635717-25-8P 635717-26-9P 635717-28-1P
635717-30-5P 635717-32-7P 635717-35-0P
635717-36-1P 635717-37-2P 635717-39-4P
635717-41-8P 635717-43-0P 635717-45-2P
635717-46-3P 635717-47-4P 635717-48-5P
635717-49-6P 635717-50-9P 635717-51-0P
635717-53-2P 635717-55-4P 635717-57-6P
635717-59-8P 635717-61-2P 635717-63-4P
635717-84-9P 635717-86-1P 635717-90-7P
635717-93-0P 635717-96-3P 635717-99-6P
635718-02-4P 635718-08-0P 635718-10-4P
635718-21-7P 635718-23-9P 635718-25-1P
635718-33-1P 635718-35-3P 635718-37-5P
635718-39-7P 635718-59-1P 635718-71-7P
635718-73-9P 635718-77-3P 635718-79-5P

635719-41-4P 635719-45-8P 635719-47-0P
 635719-53-8P 635719-57-2P 635719-73-2P
 635719-77-6P 635719-79-8P 635719-81-2P
 635719-83-4P 635719-85-6P 635719-87-8P
 635719-89-0P 635719-91-4P 635719-93-6P
 635719-95-8P 635719-97-0P 635720-02-4P
 635720-16-0P 635720-18-2P 635720-22-8P
 635720-25-1P 635720-26-2P 635720-27-3P
 635720-28-4P 635720-29-5P 635720-30-8P
 635720-34-2P 635720-36-4P 635720-38-6P
 635720-40-0P 635720-43-3P 635720-45-5P

(preparation of purinone derivs. as dipeptidylpeptidase IV inhibitors)


RN 635715-41-2 USPATFULL

CN Acetic acid, [[7-(2-chlorophenyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]oxy]-, ethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635715-40-1


CMF C20 H23 Cl N6 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635715-43-4 USPATFULL

CN Acetic acid, [[7-(2-chlorophenyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]oxy]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 635715-42-3

CMF C18 H19 Cl N6 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 635715-48-9 USPATFULL

CN Benzeneacetic acid, α -[[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]oxy]-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 635715-47-8
CMF C23 H26 N6 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 635715-52-5 USPATFULL

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-2-(1-methylpropoxy)-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635715-51-4


CMF C18 H26 N6 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635715-57-0 USPATFULL

CN Butanoic acid, 2-[[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]oxy]-, ethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635715-56-9


CMF C20 H28 N6 O4



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 635715-58-1 USPATFULL

CN Propanoic acid, 2-[[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 635715-60-5 USPATFULL

CN Propanoic acid, 2-[[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]oxy]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635715-59-2


CMF C17 H22 N6 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635715-62-7 USPATFULL

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-2-methoxy-1-methyl-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635715-61-6


CMF C15 H20 N6 O2



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 635715-63-8 USPATFULL


CN 6H-Purin-6-one, 7-(2-butynyl)-2-ethoxy-1,7-dihydro-1-methyl-8-(1-

piperazinyl)- (9CI) (CA INDEX NAME)



RN 635715-64-9 USPATFULL

CN Acetic acid, [[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 635715-66-1 USPATFULL

CN Acetic acid, [[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]oxy]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635715-65-0


CMF C16 H20 N6 O4



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 635715-68-3 USPATFULL
CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-2-(2-methoxyethoxy)-1-methyl-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 635715-67-2
CMF C17 H24 N6 O3



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 635715-79-6 USPATFULL
CN 1H-Purine-2-acetic acid, 7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-, ethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 635715-78-5
CMF C18 H24 N6 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 635715-81-0 USPATFULL

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1,2-dimethyl-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635715-80-9


CMF C15 H20 N6 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635715-83-2 USPATFULL

CN 6H-Purin-6-one, 2-butyl-7-(2-butynyl)-1,7-dihydro-1-methyl-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635715-82-1


CMF C18 H26 N6 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635715-85-4 USPATFULL

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-2-(phenylmethyl)-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635715-84-3


CMF C21 H24 N6 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635715-87-6 USPATFULL

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-2-(2-phenylethyl)-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635715-86-5


CMF C22 H26 N6 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635715-91-2 USPATFULL

CN 6H-Purin-6-one, 2-amino-7-(2-butynyl)-1,7-dihydro-1-methyl-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635715-90-1


CMF C14 H19 N7 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635715-93-4 USPATFULL

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-2-(methylamino)-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635715-92-3


CMF C15 H21 N7 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635715-95-6 USPATFULL

CN 6H-Purin-6-one, 7-(2-butynyl)-2-(dimethylamino)-1,7-dihydro-1-methyl-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635715-94-5


CMF C16 H23 N7 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635715-97-8 USPATFULL

CN Glycine, N-[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]-, ethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635715-96-7


CMF C18 H25 N7 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635715-99-0 USPATFULL

CN Glycine, N-[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635715-98-9


CMF C16 H21 N7 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635716-01-7 USPATFULL

CN Glycine, N-[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]-N-methyl-, ethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-00-6


CMF C19 H27 N7 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635716-05-1 USPATFULL

CN Glycine, N-[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]-N-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-04-0


CMF C17 H23 N7 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635716-09-5 USPATFULL

CN Alanine, N-[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-08-4


CMF C18 H25 N7 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635716-11-9 USPATFULL

CN Alanine, N-[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]-2-methyl-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-10-8


CMF C19 H27 N7 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 635716-13-1 USPATFULL


CN L-Alanine, N-[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]-, ethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-12-0

CMF C19 H27 N7 O3


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 635716-15-3 USPATFULL


CN L-Alanine, N-[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-14-2

CMF C17 H23 N7 O3


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635716-17-5 USPATFULL

CN β-Alanine, N-[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]-, ethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-16-4


CMF C19 H27 N7 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635716-19-7 USPATFULL

CN 6H-Purin-6-one, 7-(2-butynyl)-2-[(2-ethoxyethyl)amino]-1,7-dihydro-1-methyl-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-18-6


CMF C18 H27 N7 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635716-23-3 USPATFULL

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-2-[(phenylmethyl)amino]-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-22-2


CMF C21 H25 N7 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635716-27-7 USPATFULL

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-2-[methyl(phenylmethyl)amino]-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-26-6


CMF C22 H27 N7 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635716-29-9 USPATFULL

CN 6H-Purin-6-one, 7-(2-butynyl)-2-[[4-chlorophenyl)methyl]amino]-1,7-dihydro-1-methyl-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-28-8


CMF C21 H24 Cl N7 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635716-31-3 USPATFULL

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-2-[[4-methoxyphenyl)methyl]amino]-1-methyl-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-30-2


CMF C22 H27 N7 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635716-33-5 USPATFULL

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-2-[(2-phenylethyl)amino]-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-32-4


CMF C22 H27 N7 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635716-35-7 USPATFULL

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-2-[methyl(2-phenylethyl)amino]-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-34-6


CMF C23 H29 N7 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635716-39-1 USPATFULL

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-8-(1-piperazinyl)-2-[(2-pyridinylmethyl)amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-38-0


CMF C20 H24 N8 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635716-45-9 USPATFULL

CN 6H-Purin-6-one, 7-(2-butynyl)-2-(diethylamino)-1,7-dihydro-1-methyl-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-44-8


CMF C18 H27 N7 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635716-47-1 USPATFULL

CN 6H-Purin-6-one, 7-(2-butynyl)-2-(ethylmethylamino)-1,7-dihydro-1-methyl-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-46-0


CMF C17 H25 N7 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635716-53-9 USPATFULL

CN Acetonitrile, [[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]methylamino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-52-8


CMF C17 H22 N8 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635716-55-1 USPATFULL

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-2-[(1-methylethyl)amino]-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-54-0


CMF C17 H25 N7 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635716-57-3 USPATFULL

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-8-(1-piperazinyl)-2-(2-pyridinylamino)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-56-2

CMF C19 H22 N8 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635716-59-5 USPATFULL

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-2-(phenylamino)-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-58-4


CMF C20 H23 N7 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635716-65-3 USPATFULL

CN Alanine, N-[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-64-2


CMF C17 H23 N7 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635716-67-5 USPATFULL

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-8-(1-piperazinyl)-2-(2-pyridinylmethoxy)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-66-4


CMF C20 H23 N7 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635716-69-7 USPATFULL

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-2-(1-methylethoxy)-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-68-6


CMF C17 H24 N6 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635716-71-1 USPATFULL

CN 6H-Purin-6-one, 7-(2-butynyl)-2-(2-butynyloxy)-1,7-dihydro-1-methyl-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-70-0


CMF C18 H22 N6 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635716-73-3 USPATFULL

CN Acetic acid, [[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]thio]-, methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-72-2


CMF C17 H22 N6 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635716-75-5 USPATFULL

CN Propanoic acid, 2-[[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]thio]-, ethyl ester, mono(trifluoroacetate)
(9CI) (CA INDEX NAME)

CM 1

CRN 635716-74-4


CMF C19 H26 N6 O3 S



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 635716-77-7 USPATFULL
 CN Propanoic acid, 3-[[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]thio]-, ethyl ester, mono(trifluoroacetate)
 (9CI) (CA INDEX NAME)


CM 1

CRN 635716-76-6
 CMF C19 H26 N6 O3 S



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 635716-79-9 USPATFULL
 CN 6H-Purin-6-one, 7-(2-butynyl)-2-(ethylthio)-1,7-dihydro-1-methyl-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 635716-78-8
 CMF C16 H22 N6 O S



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 635716-81-3 USPATFULL

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-2-[(2-hydroxyethyl)thio]-1-methyl-8-(1-piperazinyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-80-2


CMF C16 H22 N6 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635716-86-8 USPATFULL

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-2-(methylthio)-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-85-7


CMF C15 H20 N6 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635716-90-4 USPATFULL

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-2-[(1-methylethyl)thio]-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-89-1


CMF C17 H24 N6 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635716-93-7 USPATFULL

CN 6H-Purin-6-one, 7-(2-butynyl)-2-[(1,1-dimethylethyl)thio]-1,7-dihydro-1-methyl-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-92-6


CMF C18 H26 N6 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635717-00-9 USPATFULL

CN Acetic acid, [[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]thio]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635716-99-3


CMF C16 H20 N6 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635717-02-1 USPATFULL

CN 6H-Purin-6-one, 7-(2-butynyl)-2-(ethylsulfinyl)-1,7-dihydro-1-methyl-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635717-01-0


CMF C16 H22 N6 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635717-05-4 USPATFULL

CN 6H-Purin-6-one, 7-(2-butynyl)-2-(ethylsulfonyl)-1,7-dihydro-1-methyl-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635717-04-3


CMF C16 H22 N6 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635717-08-7 USPATFULL

CN 1H-Purine-2-carbonitrile, 7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635717-07-6


CMF C15 H17 N7 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 635717-10-1 USPATFULL

CN 1H-Purine-2-carboxamide, 7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 635717-13-4 USPATFULL

CN 1H-Purine-2-carboxylic acid, 7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635717-12-3


CMF C15 H18 N6 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635717-16-7 USPATFULL

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635717-15-6


CMF C14 H18 N6 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 635717-18-9 USPATFULL


CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-2-methoxy-1-(2-phenylethyl)-8-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 635717-20-3 USPATFULL


CN 6H-Purin-6-one, 7-(2-butynyl)-2-ethoxy-1,7-dihydro-1-(2-phenylethyl)-8-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 635717-22-5 USPATFULL


CN Acetic acid, [[7-(2-butynyl)-6,7-dihydro-6-oxo-1-(2-phenylethyl)-8-(1-piperazinyl)-1H-purin-2-yl]thio]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 635717-24-7 USPATFULL


CN Glycine, N-[7-(2-butynyl)-6,7-dihydro-6-oxo-1-(2-phenylethyl)-8-(1-piperazinyl)-1H-purin-2-yl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 635717-25-8 USPATFULL


CN Acetamide, 2-[[7-(2-butynyl)-1,7-dihydro-6-oxo-1-(2-phenylethyl)-8-(1-piperazinyl)-1H-purin-2-yl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 635717-26-9 USPATFULL


CN Glycine, N-[7-(2-butynyl)-6,7-dihydro-6-oxo-1-(2-phenylethyl)-8-(1-piperazinyl)-1H-purin-2-yl]-N-methyl-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 635717-28-1 USPATFULL


CN Acetic acid, [[7-(2-butynyl)-6,7-dihydro-6-oxo-1-(2-phenylethyl)-8-(1-piperazinyl)-1H-purin-2-yl]oxy]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 635717-30-5 USPATFULL


CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-2-(2-hydroxyethoxy)-1-(2-phenylethyl)-8-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 635717-32-7 USPATFULL


CN 6H-Purin-6-one, 7-(2-butynyl)-2-(dimethylamino)-1,7-dihydro-1-(2-phenylethyl)-8-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 635717-35-0 USPATFULL


CN Benzonitrile, 2-[[7-(2-butynyl)-2-(dimethylamino)-6,7-dihydro-6-oxo-8-(1-piperazinyl)-1H-purin-1-yl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 635717-36-1 USPATFULL


CN Acetic acid, [[7-(2-butynyl)-1-[(2-cyanophenyl)methyl]-6,7-dihydro-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]thio]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 635717-37-2 USPATFULL


CN Benzonitrile, 2-[[7-(2-butynyl)-6,7-dihydro-2-methoxy-6-oxo-8-(1-piperazinyl)-1H-purin-1-yl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 635717-39-4 USPATFULL


CN Acetic acid, [[7-(2-butynyl)-1-(cyanomethyl)-6,7-dihydro-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]thio]-, methyl ester, monohydrochloride (9CI)
(CA INDEX NAME)



● HCl

RN 635717-41-8 USPATFULL


CN Acetic acid, [[1,7-di-2-butynyl-6,7-dihydro-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]thio]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 635717-43-0 USPATFULL

CN 1H-Purine-2-carbonitrile, 1,7-di-2-butynyl-6,7-dihydro-6-oxo-8-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 635717-45-2 USPATFULL
 CN 6H-Purin-6-one, 1,7-di-2-butynyl-1,7-dihydro-2-methoxy-8-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 635717-46-3 USPATFULL
 CN Acetic acid, [[7-(2-butynyl)-6,7-dihydro-6-oxo-8-(1-piperazinyl)-1-(2-propenyl)-1H-purin-2-yl]thio]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 635717-47-4 USPATFULL
 CN 1H-Purine-2-carbonitrile, 7-(2-butynyl)-6,7-dihydro-6-oxo-8-(1-piperazinyl)-1-(2-propenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 635717-48-5 USPATFULL


CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-2-methoxy-8-(1-piperazinyl)-1-(2-propenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 635717-49-6 USPATFULL


CN Acetic acid, [[7-(2-butynyl)-6,7-dihydro-1-(2-methoxyethyl)-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]thio]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 635717-50-9 USPATFULL


CN 1H-Purine-2-carbonitrile, 7-(2-butynyl)-6,7-dihydro-1-(2-methoxyethyl)-6-oxo-8-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 635717-51-0 USPATFULL

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-2-methoxy-1-(2-methoxyethyl)-8-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 635717-53-2 USPATFULL

CN 6H-Purin-6-one, 1,7-dihydro-1-methyl-7-(phenylmethyl)-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635717-52-1


CMF C17 H20 N6 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635717-55-4 USPATFULL

CN 6H-Purin-6-one, 1-ethyl-1,7-dihydro-7-(phenylmethyl)-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635717-54-3


CMF C18 H22 N6 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635717-57-6 USPATFULL

CN 1H-Purine-1-acetic acid, 6,7-dihydro-6-oxo-7-(phenylmethyl)-8-(1-piperazinyl)-, ethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635717-56-5


CMF C20 H24 N6 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635717-59-8 USPATFULL

CN 6H-Purin-6-one, 1,7-dihydro-1-(2-methoxyethyl)-7-(phenylmethyl)-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635717-58-7


CMF C19 H24 N6 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635717-61-2 USPATFULL

CN 6H-Purin-6-one, 1,7-dihydro-7-(phenylmethyl)-8-(1-piperazinyl)-1-(2-propynyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635717-60-1


CMF C19 H20 N6 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635717-63-4 USPATFULL

CN 1H-Purine-1-acetonitrile, 6,7-dihydro-6-oxo-7-(phenylmethyl)-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635717-62-3


CMF C18 H19 N7 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 635717-84-9 USPATFULL


CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-2-[(3-hydroxypropyl)thio]-1-methyl-8-(1-piperazinyl)-, mono(trifluoroacetate) (salt) (9CI) (CA

INDEX NAME)

CM 1

CRN 635717-83-8


CMF C17 H24 N6 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635717-86-1 USPATFULL

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-2-[(2-hydroxypropyl)thio]-1-methyl-8-(1-piperazinyl)-, mono(trifluoroacetate) (salt) (9CI) (CA
INDEX NAME)

CM 1

CRN 635717-85-0


CMF C17 H24 N6 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635717-90-7 USPATFULL

CN 6H-Purin-6-one, 7-(2-butynyl)-2-[(2,3-dihydroxypropyl)thio]-1,7-dihydro-1-methyl-8-(1-piperazinyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 635717-89-4


CMF C17 H24 N6 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635717-93-0 USPATFULL

CN Propanoic acid, 3-[[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]thio]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635717-92-9


CMF C17 H22 N6 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635717-96-3 USPATFULL

CN Propanoic acid, 2-[[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]thio]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635717-95-2


CMF C17 H22 N6 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635717-99-6 USPATFULL

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-2-[(1-methylpropylthio)-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635717-98-5


CMF C18 H26 N6 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635718-02-4 USPATFULL

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-8-(1-piperazinyl)-2-(propylthio)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635718-01-3


CMF C17 H24 N6 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635718-08-0 USPATFULL

CN 6H-Purin-6-one, 7-(2-butynyl)-2-(dodecylthio)-1,7-dihydro-1-methyl-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635718-07-9


CMF C26 H42 N6 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635718-10-4 USPATFULL

CN 6H-Purin-6-one, 2-[(2-aminoethyl)thio]-7-(2-butynyl)-1,7-dihydro-1-methyl-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635718-09-1


CMF C16 H23 N7 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 635718-21-7 USPATFULL


CN L-Cysteine, S-[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635718-20-6

CMF C17 H23 N7 O3 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635718-23-9 USPATFULL

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-2-[(2-methylpropyl)thio]-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635718-22-8


CMF C18 H26 N6 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635718-25-1 USPATFULL

CN 6H-Purin-6-one, 7-(2-butynyl)-2-[(1,2-dimethylpropyl)thio]-1,7-dihydro-1-methyl-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635718-24-0


CMF C19 H28 N6 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 635718-33-1 USPATFULL


CN 6H-Purin-6-one, 7-(2-butynyl)-2-[(2-furanylmethyl)thio]-1,7-dihydro-1-

methyl-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635718-32-0


CMF C19 H22 N6 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635718-35-3 USPATFULL

CN Acetamide, 2-[[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]thio]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635718-34-2


CMF C16 H21 N7 O2 S



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 635718-37-5 USPATFULL
 CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-8-(1-piperazinyl)-2-[(2-thienylmethyl)thio]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 635718-36-4
 CMF C19 H22 N6 O S2



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 635718-39-7 USPATFULL
 CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-8-(1-piperazinyl)-2-[[1-(2-thienyl)ethyl]thio]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 635718-38-6
 CMF C20 H24 N6 O S2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635718-59-1 USPATFULL

CN Acetamide, N-[2-[[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]thio]ethyl]-, mono(trifluoroacetate) (9CI)
(CA INDEX NAME)

CM 1

CRN 635718-58-0


CMF C18 H25 N7 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635718-71-7 USPATFULL

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-8-(1-piperazinyl)-2-(2-propenylthio)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635718-70-6


CMF C17 H22 N6 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635718-73-9 USPATFULL

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-2-[[3-(methylthio)phenyl]amino]-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635718-72-8


CMF C21 H25 N7 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 635718-77-3 USPATFULL


CN Propanoic acid, 2-[[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]thio]-2-methyl-, mono(trifluoroacetate) (9CI)

(CA INDEX NAME)

CM 1

CRN 635718-76-2


CMF C18 H24 N6 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635718-79-5 USPATFULL

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-2-[methyl(1-methylethyl)amino]-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635718-78-4


CMF C18 H27 N7 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635719-41-4 USPATFULL

CN 3-Pyridinecarboxamide, 6-[[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635719-40-3

CMF C20 H23 N9 O2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635719-45-8 USPATFULL

CN Benzamide, 2-[[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]amino]-N-(1,1-dimethylethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635719-44-7


CMF C25 H32 N8 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635719-47-0 USPATFULL

CN Benzamide, 2-[[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635719-46-9


CMF C21 H24 N8 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635719-53-8 USPATFULL

CN Benzoic acid, 2-[[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]methylamino]-, mono(trifluoroacetate) (9CI)
(CA INDEX NAME)

CM 1

CRN 635719-52-7


CMF C22 H25 N7 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635719-57-2 USPATFULL

CN Benzenesulfonamide, 2-[[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635719-56-1


CMF C20 H24 N8 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635719-73-2 USPATFULL

CN 1H-Purine-2-acetonitrile, 7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635719-72-1


CMF C16 H19 N7 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635719-77-6 USPATFULL

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-2-(2-oxopropyl)-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635719-76-5


CMF C17 H22 N6 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635719-79-8 USPATFULL

CN 6H-Purin-6-one, 7-(2-butynyl)-2-ethynyl-1,7-dihydro-1-methyl-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635719-78-7


CMF C16 H18 N6 O



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 635719-81-2 USPATFULL
 CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-1-methyl-2-[(1-methylethyl)sulfinyl]-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI)
 (CA INDEX NAME)


CM 1

CRN 635719-80-1
 CMF C17 H24 N6 O2 S



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 635719-83-4 USPATFULL
 CN Acetamide, N-acetyl-N-[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 635719-82-3
 CMF C18 H23 N7 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635719-85-6 USPATFULL

CN Acetamide, N-[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635719-84-5


CMF C16 H21 N7 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635719-87-8 USPATFULL

CN Acetonitrile, [[7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]oxy]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635719-86-7


CMF C16 H19 N7 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635719-89-0 USPATFULL

CN Guanidine, [7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)-1H-purin-2-yl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635719-88-9


CMF C15 H21 N9 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635719-91-4 USPATFULL

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-2-(methylthio)-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635719-90-3


CMF C14 H18 N6 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635719-93-6 USPATFULL

CN 6H-Purin-6-one, 7-(2-butynyl)-1,7-dihydro-2-[(1-methylethyl)thio]-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635719-92-5


CMF C16 H22 N6 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635719-95-8 USPATFULL

CN 6H-Purin-6-one, 7-(2-butynyl)-2-[(1,1-dimethylethyl)thio]-1,7-dihydro-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635719-94-7


CMF C17 H24 N6 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635719-97-0 USPATFULL

CN 1H-Purine-2-carbonitrile, 7-(2-butynyl)-6,7-dihydro-6-oxo-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635719-96-9


CMF C14 H15 N7 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 635720-02-4 USPATFULL

CN 1H-Purine-2-carbonitrile, 7-(2-butynyl)-1-[(2-cyanophenyl)methyl]-6,7-dihydro-6-oxo-8-(1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 635720-16-0 USPATFULL

CN 1H-Purine-2-carbonitrile, 7-(2-butynyl)-1-[(4-cyanophenyl)methyl]-6,7-dihydro-6-oxo-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635720-15-9


CMF C22 H20 N8 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635720-18-2 USPATFULL

CN Benzonitrile, 4-[[7-(2-butynyl)-6,7-dihydro-2-(methylthio)-6-oxo-8-(1-piperazinyl)-1H-purin-1-yl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635720-17-1


CMF C22 H23 N7 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 635720-22-8 USPATFULL


CN 1H-Purine-2-carbonitrile, 7-(2-butynyl)-1-[(3-cyanophenyl)methyl]-6,7-

dihydro-6-oxo-8-(1-piperazinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635720-21-7


CMF C22 H20 N8 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 635720-25-1 USPATFULL


CN 1H-Purine-2-carbonitrile, 8-(3-amino-1-piperidinyl)-7-(2-butynyl)-1-[(2-cyanophenyl)methyl]-6,7-dihydro-6-oxo-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 635720-26-2 USPATFULL


CN Benzonitrile, 2-[[8-(3-amino-1-piperidinyl)-7-(2-butynyl)-6,7-dihydro-2-methoxy-6-oxo-1H-purin-1-yl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 635720-27-3 USPATFULL


CN 1H-Purine-2-carbonitrile, 8-(3-amino-1-piperidinyl)-7-(2-butynyl)-6,7-dihydro-6-oxo-1-(2-phenylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 635720-28-4 USPATFULL


CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-7-(2-butynyl)-1,7-dihydro-2-methoxy-1-(2-phenylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 635720-29-5 USPATFULL


CN 1H-Purine-2-carbonitrile, 8-(3-amino-1-piperidinyl)-7-(2-butynyl)-1-[(4-cyanophenyl)methyl]-6,7-dihydro-6-oxo-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 635720-30-8 USPATFULL

CN Benzonitrile, 4-[[8-(3-amino-1-piperidinyl)-7-(2-butynyl)-6,7-dihydro-2-methoxy-6-oxo-1H-purin-1-yl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 635720-34-2 USPATFULL

CN 1H-Purine-2-carbonitrile, 8-(3-amino-1-piperidinyl)-7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635720-33-1


CMF C16 H19 N7 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635720-36-4 USPATFULL

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-7-(2-butynyl)-2-[(1,1-dimethylethyl)thio]-1,7-dihydro-1-methyl-, mono(trifluoroacetate) (9CI)
(CA INDEX NAME)

CM 1

CRN 635720-35-3


CMF C19 H28 N6 O S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635720-38-6 USPATFULL

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-7-(2-butynyl)-1,7-dihydro-2-methoxy-1-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635720-37-5


CMF C16 H22 N6 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 635720-40-0 USPATFULL

CN 6H-Purin-6-one, 8-(3-amino-1-piperidinyl)-7-(2-butynyl)-2-(diethylamino)-1,7-dihydro-1-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 635720-39-7


CMF C19 H29 N7 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 635720-43-3 USPATFULL


CN 1H-Purine-2-carbonitrile, 7-(2-butynyl)-6,7-dihydro-1-methyl-8-[3-(methylamino)-1-piperidinyl]-6-oxo-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 635720-45-5 USPATFULL

CN 1H-Purine-2-carbonitrile, 8-(3-amino-1-pyrrolidinyl)-7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

IT 635717-07-6 635723-88-5

(preparation of purinone derivs. as dipeptidylpeptidase IV inhibitors)


RN 635717-07-6 USPATFULL

CN 1H-Purine-2-carbonitrile, 7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-8-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 635723-88-5 USPATFULL

CN 1H-Purine-2-carbonitrile, 7-(2-butynyl)-1-[(2-cyanophenyl)methyl]-6,7-dihydro-6-oxo-8-(1-piperazinyl)- (9CI) (CA INDEX NAME)




IT 635722-55-3P 635722-62-2P 635722-67-7P
 635722-85-9P 635722-93-9P 635723-71-6P
 635723-77-2P

(preparation of purinone derivs. as dipeptidylpeptidase IV inhibitors)


RN 635722-55-3 USPATFULL

CN 1-Piperazinecarboxylic acid, 4-[2-(aminocarbonyl)-7-(2-butynyl)-6,7-dihydro-1-methyl-6-oxo-1H-purin-8-yl]-, 1,1-dimethylethyl ester (9CI)
 (CA INDEX NAME)




RN 635722-62-2 USPATFULL

CN 1-Piperazinecarboxylic acid, 4-[7-(2-butynyl)-1-[(2-cyanophenyl)methyl]-2-(dimethylamino)-6,7-dihydro-6-oxo-1H-purin-8-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 635722-67-7 USPATFULL


CN 1-Piperazinecarboxylic acid, 4-[6,7-dihydro-6-oxo-7-(phenylmethyl)-1H-purin-8-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 635722-85-9 USPATFULL


CN 1-Piperazinecarboxylic acid, 4-[7-(2-butynyl)-2-cyano-1-[(2-

cyanophenyl)methyl]-6,7-dihydro-6-oxo-1H-purin-8-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 635722-93-9 USPATFULL

CN Carbamic acid, [1-[7-(2-butynyl)-2-cyano-1-[(2-cyanophenyl)methyl]-6,7-dihydro-6-oxo-1H-purin-8-yl]-3-piperidiny]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 635723-71-6 USPATFULL


CN 1-Piperazinecarboxylic acid, 4-[7-(2-chlorophenyl)-2-(2-ethoxy-2-oxoethoxy)-6,7-dihydro-1-methyl-6-oxo-1H-purin-8-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



PAGE 1-A




PAGE 2-A



RN 635723-77-2 USPATFULL

CN 1-Piperazinecarboxylic acid, 4-[7-(2-butynyl)-2-cyano-6,7-dihydro-1-methyl-6-oxo-1H-purin-8-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L32 ANSWER 15 OF 17 USPATFULL on STN

ACCESSION NUMBER: 93:91634 USPATFULL

TITLE: (4-piperidinylmethyl and -hetero)purines

INVENTOR(S): Janssens, Frans E., Bonheiden, Belgium

Diels, Gaston S. M., Ravels, Belgium

PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Beerse, Belgium (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5258380		19931102
APPLICATION INFO.:	US 1991-719273		19910621 (7)
DISCLAIMER DATE:	20080820		
RELATED APPLN. INFO.:	Division of Ser. No. US 1989-323250, filed on 9 Mar 1989, now patented, Pat. No. US 5041448 which is a continuation of Ser. No. US 1986-858339, filed on 1 May 1986, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1985-15934	19850624
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Rizzo, Nicholas S.	
LEGAL REPRESENTATIVE:	Metz, Charles J.	
NUMBER OF CLAIMS:	6	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2450	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB (4-Piperidinylmethyl and -hetero)purines having antihistaminic properties and being useful agents in the treatment of allergic diseases.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 116062-65-8P

(preparation and alkylation of)

RN 116062-65-8 USPATFULL

CN 6H-Purin-6-one, 7-[(4-fluorophenyl)methyl]-1,7-dihydro-8-(4-piperidinylamino)-, dihydrobromide (9CI) (CA INDEX NAME)



●2 HBr


IT 116062-74-9P 116062-92-1P 116063-06-0P

116063-46-8P

(preparation of, as antiallergic agent)


RN 116062-74-9 USPATFULL

CN 6H-Purin-6-one, 8-[[1-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-4-piperidinyl]amino]-7-[(4-fluorophenyl)methyl]-1,7-dihydro- (9CI) (CA INDEX NAME)



RN 116062-92-1 USPATFULL


CN 6H-Purin-6-one, 7-[(4-fluorophenyl)methyl]-1,7-dihydro-8-[[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl]amino]- (9CI) (CA INDEX NAME)



RN 116063-06-0 USPATFULL


CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-[[7-[(4-fluorophenyl)methyl]-6,7-dihydro-6-oxo-1H-purin-8-yl]amino]-1-piperidinyl]ethyl]-2-methyl- (9CI)

(CA INDEX NAME)



RN 116063-46-8 USPATFULL

CN 6H-Purin-6-one, 7-[(4-fluorophenyl)methyl]-1,7-dihydro-8-[(1-methyl-4-piperidinyl)amino]- (9CI) (CA INDEX NAME)



L32 ANSWER 16 OF 17 USPATFULL on STN

ACCESSION NUMBER: 91:66801 USPATFULL

TITLE: (4-piperidinylmethyl and -hetero) purines

INVENTOR(S): Janssens, Frans E., Bonheiden, Belgium

Diels, Gaston S. M., Ravels, Belgium

PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Beerse, Belgium (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5041448		19910820
APPLICATION INFO.:	US 1989-323250		19890309 (7)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1986-858339, filed on 1 May 1986, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1985-15934	19850624
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Rizzo, Nicholas S.	
LEGAL REPRESENTATIVE:	Metz, Charles J.	
NUMBER OF CLAIMS:	6	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2399	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB (4-Piperidinylmethyl and -hetero)purines having antihistaminic properties and being useful agents in the treatment of allergic diseases.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 116062-65-8P

(preparation and alkylation of)

RN 116062-65-8 USPATFULL

CN 6H-Purin-6-one, 7-[(4-fluorophenyl)methyl]-1,7-dihydro-8-(4-piperidinylamino)-, dihydrobromide (9CI) (CA INDEX NAME)



●2 HBr


IT 116062-74-9P 116062-92-1P 116063-06-0P

116063-46-8P

(preparation of, as antiallergic agent)


RN 116062-74-9 USPATFULL

CN 6H-Purin-6-one, 8-[[1-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-4-piperidinyl]amino]-7-[(4-fluorophenyl)methyl]-1,7-dihydro- (9CI) (CA INDEX NAME)



RN 116062-92-1 USPATFULL


CN 6H-Purin-6-one, 7-[(4-fluorophenyl)methyl]-1,7-dihydro-8-[[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl]amino]- (9CI) (CA INDEX NAME)



RN 116063-06-0 USPATFULL


CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-[[7-[(4-fluorophenyl)methyl]-6,7-

dihydro-6-oxo-1H-purin-8-yl]amino]-1-piperidinyl]ethyl]-2-methyl- (9CI)
(CA INDEX NAME)



RN 116063-46-8 USPATFULL

CN 6H-Purin-6-one, 7-[(4-fluorophenyl)methyl]-1,7-dihydro-8-[(1-methyl-4-piperidinyl)amino]- (9CI) (CA INDEX NAME)



L32 ANSWER 17 OF 17 USPATFULL on STN

ACCESSION NUMBER: 91:30490 USPATFULL

TITLE: 2-aminopyrimidinone derivatives

INVENTOR(S): Janssens, Frans E., Bonheiden, Belgium

Kennis, Ludo E. J., Turnhout, Belgium

Sommen, Francois M., Wortel, Belgium

Dierckx, Ann C. J., Kasterlee, Belgium

PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Beerse, Belgium (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5008268		19910416
APPLICATION INFO.:	US 1989-456391		19891226 (7)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1989-380	19890109
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Ford, John M.	
LEGAL REPRESENTATIVE:	Metz, Charles J.	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1,7	
LINE COUNT:	1600	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB 2-Amino-pyrimidinone derivatives possessing antihistaminic and serotonin-antagonistic properties. Compositions containing these

compounds as the active ingredient and a method of treating subjects from allergic diseases.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 131264-36-3P

(preparation of, as antihistaminic and antiserotonergic)

RN 131264-36-3 USPATFULL

CN 1,2,4-Triazolo[4,3-a]pyrimidin-5(1H)-one, 6-[2-[4-[[7-[(4-fluorophenyl)methyl]-6,7-dihydro-6-oxo-1H-purin-8-yl]amino]-1-piperidinyl]ethyl]-1,3,7-trimethyl- (9CI) (CA INDEX NAME)




FILE 'HOME' ENTERED AT 16:37:30 ON 12 MAY 2005

=>

This Page Blank (uspto)

=> d stat que l29; d his full
L9 STR



VAR G1=C/NH2/26/H

VAR G2=H/C/N/20/22/23

VAR G3=O/S

NODE ATTRIBUTES:

NSPEC IS RC AT 13

CONNECT IS E1 RC AT 22

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:


RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 27

STEREO ATTRIBUTES: NONE

L12 35177 SEA FILE=REGISTRY SSS FUL L9

L20 STR




C @29 N @30

N~G6~N
@31 32 33

CH~G5~Cb
@34 35 36

N~G7~Cb
@37 38 39

CH~G5~N
@40 41 42



VAR G1=C/NH2/26/H

This Page Blank (uspto)

VAR G2=H/C/N/20/23
 VAR G3=O/S
 VAR G4=29/30/31/34/37/40/48
 REP G5=(0-3) CH
 REP G6=(1-4) CH
 REP G7=(0-4) CH
 REP G8=(0-2) CH
 REP G9=(1-3) C

NODE ATTRIBUTES:


NSPEC IS RC AT 13
 NSPEC IS R AT 29
 NSPEC IS R AT 30
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 47

STEREO ATTRIBUTES: NONE

L22 456 SEA FILE=REGISTRY SUB=L12 SSS FUL L20
 L24 STR



Page 1-A

CH·G15~G5
 @88 89 90

Page 2-A


VAR G3=O/S
 VAR G4=56/59/60/65/70/75/48/83/84/88
 VAR G5=NH2/49/52
 REP G6=(1-9) C

the page blank (uspio)

REP G8=(0-2) CH
 REP G9=(1-3) C
 REP G10=(2-10) C
 REP G11=(0-4) C
 REP G12=(0-3) C
 REP G13=(1-4) CH
 REP G14=(0-1) CH
 REP G15=(1-3) CH
 NODE ATTRIBUTES:
 NSPEC IS RC AT 13
 CONNECT IS E1 RC AT 50
 CONNECT IS E1 RC AT 51
 CONNECT IS E1 RC AT 53
 DEFAULT MLEVEL IS ATOM
 GGCAT IS SAT AT 67
 GGCAT IS SAT AT 72
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 60

STEREO ATTRIBUTES: NONE
 L26 STR






VAR G1=O/S
 REP G2=(1-9) CH2
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE
 L27 STR

This Page Blank (uspto)



G2 @28

VAR G1=O/S
VAR G2=NH2/14/17/19
REP G3=(0-3) C
VAR G5=NH2/14/17
VPA 28-22/27/23 U

NODE ATTRIBUTES:

CONNECT IS E1 RC AT 15
CONNECT IS E1 RC AT 16
CONNECT IS E1 RC AT 18
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 25

STEREO ATTRIBUTES: NONE

L29 .445 SEA FILE=REGISTRY SUB=L22 SSS FUL (L24 NOT (L26 OR L27))

100.0% PROCESSED 456 ITERATIONS
SEARCH TIME: 00.00.01

445 ANSWERS

(FILE 'HOME' ENTERED AT 15:05:04 ON 12 MAY 2005)

FILE 'CAPLUS' ENTERED AT 15:05:42 ON 12 MAY 2005

SET LINE 250

SET DETAIL OFF

E US2003-634047/AP, PRN 25

SET NOTICE 1000 SEARCH

L1

1 SEA ABB=ON US2003-634047/AP

SET NOTICE LOGIN SEARCH

SET LINE LOGIN

SET DETAIL LOGIN

This Page blank (uspto)

D SCAN
SEL RN

FILE 'REGISTRY' ENTERED AT 15:06:23 ON 12 MAY 2005

L2 102 SEA ABB=ON (100-39-0/BI OR 100-46-9/BI OR 103-63-9/BI OR
105-36-2/BI OR 108-91-8/BI OR 110-89-4/BI OR 110821-27-7/BI OR
124-40-3/BI OR 140-75-0/BI OR 16182-04-0/BI OR 16694-46-5/BI
OR 172603-05-3/BI OR 3218-02-8/BI OR 3277-89-2/BI OR 454712-45-
9/BI OR 454712-46-0/BI OR 454712-48-2/BI OR 454712-50-6/BI OR
459-73-4/BI OR 54249-88-6/BI OR 64-04-0/BI OR 666702-26-7/BI
OR 666702-31-4/BI OR 666702-35-8/BI OR 666702-40-5/BI OR
666702-45-0/BI OR 666702-50-7/BI OR 666702-56-3/BI OR 666702-59-
6/BI OR 666702-63-2/BI OR 666702-67-6/BI OR 666702-70-1/BI OR
666702-73-4/BI OR 666702-77-8/BI OR 666702-82-5/BI OR 666702-86-
9/BI OR 666702-89-2/BI OR 666702-91-6/BI OR 666702-94-9/BI OR
666702-97-2/BI OR 666703-02-2/BI OR 666703-05-5/BI OR 666703-09-
9/BI OR 666703-11-3/BI OR 666703-14-6/BI OR 666703-17-9/BI OR
666703-20-4/BI OR 666703-21-5/BI OR 666703-23-7/BI OR 666703-25-
9/BI OR 666703-27-1/BI OR 666703-29-3/BI OR 666703-31-7/BI OR
666703-33-9/BI OR 666703-35-1/BI OR 666703-37-3/BI OR 666703-41-
9/BI OR 666703-45-3/BI OR 666703-47-5/BI OR 666703-50-0/BI OR
666703-52-2/BI OR 666703-54-4/BI OR 666703-56-6/BI OR 666703-62-
4/BI OR 666703-64-6/BI OR 666703-66-8/BI OR 666703-68-0/BI OR
666703-70-4/BI OR 666703-72-6/BI OR 666703-74-8/BI OR 666703-76-
0/BI OR 666703-78-2/BI OR 666703-80-6/BI OR 666703-82-8/BI OR
666703-84-0/BI OR 666703-86-2/BI OR 666703-88-4/BI OR 666703-90-
8/BI OR 666703-92-0/BI OR 666703-94-2/BI OR 666703-96-4/BI OR
666703-98-6/BI OR 666704-00-3/BI OR 666704-02-5/BI OR 666704-04-
7/BI OR 666704-06-9/BI OR 666704-08-1/BI OR 666704-09-2/BI OR
666704-10-5/BI OR 666704-11-6/BI OR 666704-12-7/BI OR 666704-13-
8/BI OR 666704-14-9/BI OR 666704-15-0/BI OR 666704-16-1/BI OR
666704-19-4/BI OR 666704-74-1/BI OR 70-11-1/BI OR 74-89-5/BI
OR 75-16-1/BI OR 75-31-0/BI OR 79463-77-7/BI)
L3 82 SEA ABB=ON L2 AND NR>1
D SCAN

FILE 'STNGUIDE' ENTERED AT 15:07:28 ON 12 MAY 2005

FILE 'CAPLUS' ENTERED AT 15:09:48 ON 12 MAY 2005

SET LINE 250
SET DETAIL OFF
E US2003-636088/AP, PRN 25
SET NOTICE 1000 SEARCH
L4 1 SEA ABB=ON US2003-636088/AP
SET NOTICE LOGIN SEARCH
SET LINE LOGIN
SET DETAIL LOGIN
D SCAN
SEL RN

FILE 'REGISTRY' ENTERED AT 15:10:44 ON 12 MAY 2005

L5 44 SEA ABB=ON (172603-05-3/BI OR 4023-34-1/BI OR 454709-00-3/BI
OR 454709-69-4/BI OR 454711-07-0/BI OR 454712-87-9/BI OR
54249-88-6/BI OR 666816-75-7/BI OR 666816-76-8/BI OR 666816-77-
9/BI OR 666816-78-0/BI OR 666816-79-1/BI OR 666816-80-4/BI OR
666816-81-5/BI OR 666816-82-6/BI OR 666816-83-7/BI OR 666816-84-
8/BI OR 666816-85-9/BI OR 666816-86-0/BI OR 666816-87-1/BI OR
666816-88-2/BI OR 666816-89-3/BI OR 666816-90-6/BI OR 666816-91-
7/BI OR 666816-92-8/BI OR 666816-93-9/BI OR 666816-94-0/BI OR
666816-95-1/BI OR 666816-96-2/BI OR 666816-97-3/BI OR 666816-98

This Page Blank (uspto)

-4/BI OR 666816-99-5/BI OR 666817-00-1/BI OR 666817-01-2/BI OR
666817-02-3/BI OR 666817-03-4/BI OR 666817-04-5/BI OR 666817-05
-6/BI OR 666817-06-7/BI OR 666817-07-8/BI OR 6851-99-6/BI OR
77350-93-7/BI OR 870-63-3/BI OR 9007-12-9/BI)

L6 38 SEA ABB=ON L5 AND NR>1
D SCAN

FILE 'STNGUIDE' ENTERED AT 15:12:41 ON 12 MAY 2005

FILE 'REGISTRY' ENTERED AT 15:22:37 ON 12 MAY 2005

L7 STR
L8 50 SEA SSS SAM L7
L9 STR L7
L10 50 SEA SSS SAM L9

FILE 'STNGUIDE' ENTERED AT 15:26:40 ON 12 MAY 2005

FILE 'REGISTRY' ENTERED AT 15:31:31 ON 12 MAY 2005

D QUE L10
L11 50 SEA SSS SAM L9
L12 35177 SEA SSS FUL L9
SAVE TEMP L12 BER088FULL/A
L13 STR L9
L14 2 SEA SUB=L12 SSS SAM L13
D SCAN
L15 52 SEA SUB=L12 SSS FUL L13
SAVE TEMP L15 BER088SUB/A

FILE 'CAPLUS' ENTERED AT 15:39:06 ON 12 MAY 2005

L16 5 SEA ABB=ON L15

FILE 'REGISTRY' ENTERED AT 15:39:17 ON 12 MAY 2005

L17 ANALYZE L15 1- LC : 3 TERMS
D

FILE 'REGISTRY' ENTERED AT 15:40:26 ON 12 MAY 2005

D STAT QUE L15

FILE 'CAPLUS, USPATFULL' ENTERED AT 15:40:26 ON 12 MAY 2005

L18 8 SEA ABB=ON L15
L19 8 DUP REM L18 (0 DUPLICATES REMOVED)
ANSWERS '1-5' FROM FILE CAPLUS
ANSWERS '6-8' FROM FILE USPATFULL
D IBIB ED ABS HITSTR 1-8

FILE 'HOME' ENTERED AT 15:40:49 ON 12 MAY 2005

D STAT QUE L15

FILE 'REGISTRY' ENTERED AT 15:44:34 ON 12 MAY 2005

D QUE L12
L20 STR L9
L21 24 SEA SUB=L12 SSS SAM L20
L22 456 SEA SUB=L12 SSS FUL L20
SAVE TEMP L22 BER047SUB1/A

FILE 'CAPLUS' ENTERED AT 15:50:41 ON 12 MAY 2005

L23 16 SEA ABB=ON L22

FILE 'REGISTRY' ENTERED AT 16:19:18 ON 12 MAY 2005

L24 STR L20

This Page Blank (uspto)

L25 STR
L26 STR L25,
L27 STR L26
L28 27 SEA SUB=L22 SSS SAM (L24 NOT (L26 OR L27))
L29 445 SEA SUB=L22 SSS FUL (L24 NOT (L26 OR L27))
SAVE TEMP L29 BER047SUB/A
L30 ANALYZE L29 1- LC : 5 TERMS
D

FILE 'REGISTRY' ENTERED AT 16:36:06 ON 12 MAY 2005
D STAT QUE L29

FILE 'CAPLUS, USPATFULL, TOXCENTER' ENTERED AT 16:36:06 ON 12 MAY 2005
L31 22 SEA ABB=ON L29
L32 17 DUP REM L31 (5 DUPLICATES REMOVED)
ANSWERS '1-12' FROM FILE CAPLUS
ANSWERS '13-17' FROM FILE USPATFULL
D IBIB ED ABS HITSTR 1-17

FILE 'HOME' ENTERED AT 16:37:30 ON 12 MAY 2005
D STAT QUE L29
D STAT QUE L29

FILE HOME

FILE CAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 May 2005 VOL 142 ISS 20
FILE LAST UPDATED: 11 May 2005 (20050511/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 11 MAY 2005 HIGHEST RN 850303-40-1
DICTIONARY FILE UPDATES: 11 MAY 2005 HIGHEST RN 850303-40-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

This Page blank (uspto)

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

FILE STNGUIDE
FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May 6, 2005 (20050506/UP).

FILE USPATFULL
FILE COVERS 1971 TO PATENT PUBLICATION DATE: 12 May 2005 (20050512/PD)
FILE LAST UPDATED: 12 May 2005 (20050512/ED)
HIGHEST GRANTED PATENT NUMBER: US6892391
HIGHEST APPLICATION PUBLICATION NUMBER: US2005102725
CA INDEXING IS CURRENT THROUGH 12 May 2005 (20050512/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 12 May 2005 (20050512/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2005
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2005

>>> USPAT2 is now available. USPATFULL contains full text of the <<<
>>> original, i.e., the earliest published granted patents or <<<
>>> applications. USPAT2 contains full text of the latest US <<<
>>> publications, starting in 2001, for the inventions covered in <<<
>>> USPATFULL. A USPATFULL record contains not only the original <<<
>>> published document but also a list of any subsequent <<<
>>> publications. The publication number, patent kind code, and <<<
>>> publication date for all the US publications for an invention <<<
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<
>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc. <<<

>>> USPATFULL and USPAT2 can be accessed and searched together <<<
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<
>>> enter this cluster. <<<
>>> <<<
>>> Use USPATALL when searching terms such as patent assignees, <<<
>>> classifications, or claims, that may potentially change from <<<
>>> the earliest to the latest publication. <<<

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE TOXCENTER

FILE COVERS 1907 TO 10 May 2005 (20050510/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This Page Blank (uspto)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TOXCENTER has been enhanced with new files segments and search fields.
See HELP CONTENT for more information.

TOXCENTER thesauri in the /CN, /CT, and /MN fields incorporate the
MeSH 2005 vocabulary. See <http://www.nlm.nih.gov/mesh/> and
http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html for a
description of changes.

=>

This Page Blank (uspto)